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Abstract 
Natural products are a prime source of “lead” compounds whose full potential still remains 
untapped. These lead compounds owe their biological diversity to a broad spectrum of 
mechanisms which are often difficult to elucidate. This study applied high content analysis 
methods as a first step to get hints towards the mode of action (MoA) of a set of compounds 
of interest. These methods included two cell-based approaches, one based on automated 
microscopy which provides information on the action of the compounds in the form of 
immunofluorescence images and the other based on the xCELLigence system providing 
impedance curves as a result of a real-time monitoring of cell perturbations. Profiles from 
individual approaches were compared with those of reference compounds whose 
mechanisms were known and well established. 
Indications provided by HCA formed the basis for elucidating the MoA of few selected 
bioactive compounds, namely jerantinine E, paleo-soraphen A & B, and Dsz A1 and Z. The 
cytotoxicity of these compounds varied from micro- to subnanomolar ranges in cancer cells. 
Their activities could be attributed to different mechanisms. Jerantinine E, an indole alkaloid, 
induced a depletion of the microtubular network of cells. It inhibited the tubulin 
polymerisation in vitro in low micromolar ranges. Paleo-soraphen A & B, genetic derivatives 
of soraphen A, were not only less active than their parent compound but also seem to have 
different mechanisms supporting the concept of evolutionary optimization. Paleo-soraphen A 
on one hand showed a mechanism similar to that of soraphen A whereas paleo-soraphen B 
seems to deviate. It showed effects that are similar to the topoisomerase I inhibitor 
camptothecin.  
Most potent among all were disorazol (Dsz) A1 and Z which have been known as tubulin 
polymerisation inhibitors. Detailed investigations presented here revealed additional targets 
that have been overlooked so far. These targets are addressed at even lower 
concentrations. Drug affinity responsive target stability (DARTS) approaches showed that 
Dsz A1 binds to the phosphatase enzyme PTEN which antagonizes the PI3K/Akt pathway 
whereas Dsz Z targets the regulatory unit of PI3 kinase, p85. Western blot analysis provided 
the interesting revelation that Dsz A1 and Z, though showing structural similarity have 
different targets and are affecting different pathways. Dsz A1 on one hand affects the 
PI3K/Akt pathway whereas the effect of Dsz Z is independent of Akt. It stalls the PI3K/SGK 
pathway. Dsz Z induces a dephosphorylation of p85. Knockdown studies of the respective 
target proteins confirmed their involvement in the different pathways. Measuring mono- and 
oligonucleosome enrichment confirmed the decisive role of PTEN in apoptosis induction by 
Dsz A1. Docking studies conducted on PTEN with Dsz A1 showed an important interaction of 
the epoxide group with the amino acids Arg172, 173 and Thr319. Caspase activity 
measurements in knockdown cells provided evidence of the role played by p85 in apoptosis 
induction by Dsz Z. 
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Zusammenfassung 
Naturstoffe sind eine vorzügliche Quelle für Leitstrukturen, deren Potential bei weitem noch 
nicht ausgeschöpft ist. Diese Leitstrukturen verdanken ihre biologische Vielfalt einem breiten 
Spektrum an Wirkmechanismen, die aber oft schwierig aufzuklären sind. Diese Studie 
benutzte „High-Content“-Analysemethoden als ersten Schritt, um Hinweise auf den 
Wirkmechanismus ausgewählter Verbindungen zu bekommen. Diese Methoden umfassten 
zwei zell-basierte Ansätze; einer basierend auf automatischer Mikroskopie liefert 
Informationen über die Wirkung von Verbindungen in Form von Immunfluoreszenz-Bildern 
und der andere basierend dem xCELLigence-System Impedanzkurven als Ergebnis eines 
Echtzeit-Monitoring von Zellstörungen. Die Profile der individuellen Ansätze wurden mit 
denen von Referenz-Verbindungen verglichen, deren Wirkmechanismus bekannt und gut 
untersucht ist. 
Die Hinweise aus der High-Content-Analyse bildeten die Grundlage für die Aufklärung der 
Wirkmechanismen einiger ausgewählter bioaktiver Verbindungen: Jerantinine E, Paläo-
Soraphen A und B und Disorazol A1 und Z. Die Zytotoxizität dieser Verbindungen bei 
Krebszellen lag im mikro- bis subnanomolaren Bereich. Ihre Aktivitäten konnten auf 
verschiedene Wirkmechanismen zurückgeführt werden. Das Indolalkaloid Jerantinine E 
führte zu einem Abbau des mikrotubulären Netzes der Zelle. Es hemmte die 
Tubulinpolymerisation in vitro im unteren mikromolaren Bereich. Paläo-Soraphen A und B, 
„genetische“ Derivate von Soraphen A, waren nicht nur weniger aktiv als die 
Mutterverbindung, sie scheinen auch verschiedene Wirkmechanismen zu haben, was das 
Konzept einer evolutionären Optimierung unterstützt. Während Paläo-Soraphen A einen 
Wirkmechanismus ähnlich dem von Soraphen A zeigte, scheint Paläo-Soraphen B davon 
abzuweichen. Es zeigte Effekte, die dem Topoisomerase-I-Hemmer Camptothecin ähnlich 
sind. 
Am wirksamsten waren Disorazol (Dsz) A1 und Z, die bislang als Hemmer der Tubulin-
Polymerisation bekannt waren. Die hier vorgestellten detaillierten Untersuchungen haben 
zusätzliche Zielproteine aufgedeckt, die bislang übersehen wurden. Diese werden sogar bei 
noch niedrigeren Konzentrationen adressiert. DARTS-Ansätze (drug affinity responsive 
target stability) zeigten, dass Dsz A1 an das Phosphatase-Enzym PTEN bindet, was zu einer 
Hemmung des PI3K/Akt-Signalwegs führt, während Dsz Z auf p85 abzielt, die regulatorische 
Einheit der PI3-Kinase. Western-Blot-Analysen lieferten den interessanten Befund, dass Dsz 
A1 und Z, obwohl sie strukturelle Ähnlichkeiten zeigen, verschiedene Zielproteine haben und 
auf verschiedene Signalwege einwirken. Dsz A1 beeinflusst den PI3K/Akt-Signalweg, 
während der Effekt von Dsz Z unabhängig von Akt ist. Es blockiert den PI3K/SGK-
Signalweg. Dsz Z induziert eine Dephosphorylierung von p85. Knockdown-Studien mit den 
entsprechenden Zielproteinen bestätigten ihre Einbindung in die verschiedenen Signalwege. 
Eine Messung der Anreicherung von Mono- und Oligonuclesomen bestätigte die 
maßgebende Rolle von PTEN in der Apoptose-Induktion durch Dsz A1. Docking-Studien mit 
PTEN und Dsz A1 zeigten eine wichtige Interaktion der Epoxidgruppe mit den Aminosäuren 
Arg172, 173 und Thr319. Caspase-Aktivitätsmessungen in Knockdown-Zellen belegten die Rolle 
von p85 in der durch Dsz Z induzierten Apoptose. 
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1 Introduction 
Natural products are naturally derived metabolites and products from microorganisms, plants 
and animals. These products have been exploited for human use for thousands of years. It 
was not until Pasteur discovered that fermentation is caused by living cells that ushered in 
the antibiotic era which started with discovery and development of penicillin from fungus 
Penicillium notatum (Strobel et al., 2004). From this point on microbes were investigated as 
a source of bioactive natural products.  
Natural products are the most productive source of leads for drug development. Well over 
80% of drug substances are derived from natural products or inspired from them (Newman 
et al., 2000). They cover a range of therapeutic indications like anti-cancer, anti-infectives, 
and anti-diabetics, among others (Harvey, 2008). Undoubtedly, the major producers of 
secondary metabolites are members of the Actinomycetales, especially from the genus 
Streptomyces, followed by Bacillus as well as Pseudomonas. However, over the last 
decades, myxobacteria have emerged as promising source of bioactive molecules. Natural 
products derived from myxobacteria exhibits many unique structural features as well as 
novel mode of actions making them attractive lead structures for drug development 
(Weissman and Muller, 2009). 
1.1 Myxobacteria and their secondary metabolism 
The work of the Höﬂe and Reichenbach research groups at HZI, Braunschweig, Germany 
resulted in the isolation of more than 7500 myxobacterial strains, all of which are currently 
housed in the institute’s collection and at DSMZ (Deutsche Sammlung von Mikroorganismen 
und Zellkulturen) (Weissman and Muller, 2009). 
Myxobacteria are Gram-negative δ-proteobacteria occupying habitats ranging from soil to 
bark of trees, decaying plant materials and marine environment (Wenzel and Muller, 2009). 
They secrete exo-enzymes which allow them to use a range of biological macromolecules 
like cellulose as food source which also includes whole microorganisms such as fungi and 
bacteria. During unfavourable growth conditions, cells aggregate to form a 
pseudoplasmodium-like slimy mass which ultimately transforms into a complex, multi-cellular 
fruiting body harbouring propagative spores (Weissman and Muller, 2010).  
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Figure 1.1: Myxobacterial producers of novel secondary metabolites (adapted from (Gerth et 
al., 2003) 
Among myxobacteria (Figure 1.1), the genus Sorangium is particularly valuable, as 48.4% of 
the metabolites isolated from myxobacteria, including the potent anti-tumour compound 
epothilone, derive from this group. The majority of myxobacterial metabolites are 
polyketides, nonribosomal polypeptides or hybrids of the two structures, many of which are 
synthesized on huge molecular assembly lines composed of polyketide synthase (PKS) and 
nonribosomal polypeptide synthase (NRPS) multienzymes (Schneiker et al., 2007). Many of 
the myxobacterial metabolites not only belong to multiple structural classes but also have 
number of chemical variants. Furthermore, the genome of several strains has been 
sequenced and shown that the myxobacteria have greater secondary metabolite producing 
ability than suggested by its fermentation under standard laboratory conditions. Sorangium 
cellulosum So ce56 has by far the largest known sequenced genome from any bacterium 
(13 Mbp) which correlates to its ability of secondary metabolism (Weissman and Muller, 
2010). 
Sorangium strains exhibit physiological features of myxobacteria like movement by gliding, 
biofilm formation and fruiting body formation as depicted in Figure 1.2. 
Natural products are the end products of complex multistep biosynthetic processes. As 
mentioned earlier two major multifunctional enzyme systems called polyketide synthases 
(PKS) and non-ribosomal peptide synthases (NRPS) assemble simple building blocks such 
as coenzyme-A-activated carboxylic acids and amino acids to form secondary metabolites. 
Mostly secondary metabolites are derived from modular PKS and NRPS megasynthases but 
many of them are frequently directed by a mixed PKS-NRPS system. Even when the 
myxobacteria adhere to a single megasynthase, they deviate from the norm and show 
Sorangium (48.4 %) 
Myxococcus (20.7 %) 
Chondromyces (10.3 %) 
Stigmatella (6.9 %) 
Polyangium (5.2 %) 
Nannocystis (1.7 %) 
Melittangium (1.7 %) 
Cystobacter (1.7 %) 
Angiococcus (1.7 %) 
Corallococcus (1.7 %) 
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iterative use of modules, module skipping or unusual arrangement of core domains within 
the module (Wenzel and Muller, 2007). 
 
Figure 1.2: Physiological characteristics of S. cellulosum So ce56 
(A). S. cellulosum colonies. (B, C) Swarming growth patterns. (D) Fruiting bodies. (E) Growth on 
cellulose as sole carbon source. (F) Adherence to crystalline cellulose (Schneiker et al., 2007) 
The most commonly observed bioactivity among myxobacterial metabolites is anti-
yeast/fungal at 54% followed by antibacterial activity at 29%. Other bioactivities like anti-
malarial, immunosuppressive, insecticidal and herbicidal activities are rare but noteworthy. 
The most famous group of compound isolated from myxobacteria up to now are the 
epothilones that were discovered in Sorangium cellulosum. The epothilones interfere with 
(A) (B) 
(C) (D) 
(E) (F) 
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the dynamic of the tubulin/microtubule system in the cells. They induce a stabilization of 
microtubules and thereby show the mode of action similar to taxol, a compound originally 
isolated from the bark of the Pacific yew tree that was approved as an anti-cancer drug in 
the 1990s. A semi-synthetic analogue of epothilone B, ixabepilone, was also approved for 
clinical use in the US for treatment of aggressive breast cancer in 2007 as it is active not 
only against taxol-resistant tumours but also multi-resistant P-glycoprotein expressing 
tumours (Weissman and Muller, 2010; Zhao et al., 2013). 
1.2 High Content Analysis 
Early stages of the drug discovery process form a continuous pipeline of steps including 
target identification, target selection, primary screening and candidate optimization (Giuliano, 
1997). Target identification involves selecting a target generally a gene or a protein, which is 
involved in pathophysiology of a disease. This target should be able to interact with and be 
affected by the drug. This is followed by target validation which is to confirm that the target is 
actually involved in the disease. These two steps are performed by scientists who deal with 
people at clinical level like physicians. Once the target is validated through experiments both 
in vitro and in vivo scientists now could look for suitable drug against these targets 
(www.innovation.org). They search for a molecule or “lead” compound that may act on the 
validated target to change the course of the disease for good. These lead compounds could 
come from any source ranging from nature to chemically synthesized compounds to 
genetically engineered biomolecules. As we have seen earlier nature provides us with 
plethora of options for lead compounds that could fight against many diseases. In order to 
scan through all the bioactive molecules one requires rapid screening and hit identification 
methods. High throughput screening (HTS) is one such tool which identifies natural products 
and synthetic molecules as potential drug leads using automated screening of large 
collections (libraries) of compounds for activity as inhibitors or activators of specific biological 
targets (Koehn and Carter, 2005). Once bioactive molecules have been screened and 
identified, these could be analysed further for their specificity and mechanism making use of 
high content analysis (HCA) methods (Bickle, 2010) . 
Cell-based assays proved to be a very useful tool to investigate the effect of compound 
treatment within cellular context overcoming the limitations of biochemical assays (Denner et 
al., 2008). These cell-based assays could be labelled for detecting various cellular functions. 
Typical detection methods available are based on radioisotopes, optical absorbance, 
fluorescence and luminescence which require labelling of ligand, enzyme or tracer 
molecules. Other detection technologies which are label-free are well emerging in the past 
several years, including acoustic field-based detection and electrical detection based on cell-
substrate impedance measurement.   
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1.2.1 Automated Microscopy 
Visual assays, in which a target of interest is labelled with a fluorophor and observed using a 
microscope, are notable among other types of assays in terms of the amount and the quality 
of information acquired from a single assay (Carpenter, 2007). Image-based assays provide 
us with information ranging from a general phenotype such as the cell’s health to a very 
specific phenotype such as localization of phosphorylated form of a protein. Even a single 
label such as nuclear staining can not only allow counting the number of cells but also 
indicate cell cycle progression and apoptotic state based on measurement of its DNA 
content and morphology. Such rich information is collected from individual cells and hence 
the term “high content”. 
However, results of such approach have shown limited statistical validation due to low-
throughput owing to restricted size of samples analysed, requiring laborious manual 
collection of images followed by visual inspection of thousands of images (Carpenter, 2007; 
Denner et al., 2008). To overcome these shortcomings, two major technologies, automated 
microscopes and cell image analysis software have gathered attention and made image-
based assays adaptable to high throughput analysis of small-molecules. The resulting 
process has earned the name “high throughput high content analysis” (Carpenter, 2007). 
An automated microscope is equipped with a digitally charged coupled device (CCD) 
camera allowing machine-readable measures of cell perturbation caused by compound 
treatment and employs a software environment for automated analysis of acquired images to 
quantify cellular processes (Denner et al., 2008; Perlman et al., 2004). 
For the success of automated analysis of “hit” compounds, the scope of variability should be 
kept to minimum, starting with cells used for high content analysis which should be checked 
for their quality to provide high-quality and consistent cell preparations. Selected cells are 
harvested and dispensed into 384/1536-well microtitre plates (MTPs) with transparent 
bottom for microscopy. This particular step could either be manual or robotic however 
automated dispensers are preferred for fast generation of cell plates from constantly stirred 
cell suspensions using minimal sheering force. 
Depending on the cell concentration and the rate of growth, cell plates are incubated under 
optimal conditions and then treated with small-molecule libraries which are dissolved in 
dimethylsulphoxide (DMSO). To reduce assay variance, multiple cell plates could be treated 
with the same library plate. All small molecules are either present at a single concentration 
or multiple concentrations in case of dose-response analysis. Drugs with known mode of 
action were selected to later compare the cell phenotype of the test compounds with that of 
known drugs. After optimal incubation of the cells with the compound, cells are fixed and 
labelled with one or more antibodies and a nuclear marker (Shariff et al., 2010). 
Following sample preparation in which cellular targets are labelled with fluorophors, an 
automated microscope is used for acquiring the images. Software associated with such a 
microscope allows predefinition of microscope processes that makes unattended image 
acquisition possible (Figure 1.3). 
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Automated image analysis helps to quantify and 
correlate multiple phenotypic responses. Fluorescent 
signals that serve as readout for a specific cellular 
phenotype has to be defined with the analysis 
software. Parameters such as intensity measurement, 
cell size and shape are considered. Background 
signals are separated by setting a threshold value for 
each fluorescence channel. The image algorithm scans 
through the images based on these defined 
specifications. This process provides us with numerical 
data obtained from images which are analysed later 
using different statistical methods to provide us with 
clusters of test compounds with reference compounds. 
Follow-up experiments are carried out later to confirm 
the findings of automated microscopy. 
Figure 1.3: Major steps for high-throughput analysis 
using an automated microscope (Carpenter, 2007). 
Although high content image analysis provides us with 
rich information, it is still limiting in terms of cost and 
time of labelling, loss of cells due to several cell-
washing steps, interference with physiological 
condition by the labelling molecule and most 
importantly this assay is a single-point assay which can 
only provide us with a “snapshot” of the experiment 
(Atienza et al., 2006; Solly et al., 2004) and not a 
kinetic measurement. Therefore it becomes essential 
to lookout for assays which are non-invasive and 
provide us with kinetic data of biological and cellular 
processes. A detailed description of one such an 
approach adapted for this study is shown in the 
following section. 
1.2.2 xCELLigence – Impedance measurement 
Giaever et al. in 1984 first reported of electrical cell-substrate impedance sensing (ECIS) for 
real-time measurement of cellular processes. Several reports have since been shown to use 
this technology for monitoring cellular processes like macrophage adherence and their 
activation, change in cell morphology due to cytoskeletal rearrangement, cell migration etc.  
Impedance-based real-time cell analysis (RTCA, also trademarked as xCELLigence) system 
is another variation of ECIS which helps in a number of biological assays including cell 
proliferation, cytotoxicity, cell growth inhibition and apoptosis assays. RTCA system (ACEA 
Biosciences Inc., San Diego, CA) consists of four components: the electronic microtitre 
plates (E-plate™), RTCA-SP (single plate), which is placed inside an incubator maintained at 
optimal temperature and CO2 condition, an electronic sensor analyser, which sends and 
receives electronic signals and a computer which runs the RT-CES (Real time cell electronic 
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sensing) software and continuously acquires and displays the data (Atienza et al., 2006). 
This is a label free non-invasive cell-based assay which was used in this study.  
Principle of RT-CES 
The basic principle of RTCA is similar to that described by Giaever and co-workers for ECIS. 
The ionic environment present both at the electrode/solution interface and in the bulk 
solution determine the electronic impedance of an electrode. This ionic environment 
undergoes a change through field-directed movement and concentration gradient-driven 
diffusion under applied electrical field. Inside an electrolyte solution, total electrode 
impedance has two components: resistance of the solution itself whose contribution is so 
small that it is ignored and the impedance at the electrode/solution interface. Whereas in the 
presence of cells, the local ionic environment changes leading to addition of the third 
component: impedance of cells. The more the number of cells that attach to the electrodes, 
the larger would be the change in electrode impedance which is further increased upon the 
extent of cell’s attachment as shown in Figure 1.4 (Solly et al., 2004). 
 
Figure 1.4: Electrode impedance plotted against time  
With time, cells attach and spread on the electrode. As the time passes, with the same number of 
cells at the start point, impedance increases due to better cell attachment and its spread over the 
electrode (Solly et al., 2004). 
In the RTCA system, an electronic analyser measures the electrode impedance. A voltage of 
10 mV AC is applied to the electrode for ~0.1 s to pass electrical current through the circuit. 
This voltage does not disturb the cell function as it is much smaller than the resting potential 
of a typical mammalian cell which was proved in an experiment involving NIH 3T3 fibroblast 
cells. There was no notable change in their proliferation after application of 200 mV, 10 kHz 
voltage signals to the electrode for ~30 min (Solly et al., 2004). 
A dimensionless parameter, Cell Index (CI) is derived as a relative change in measured 
electrical impedance to represent cell status. A CI of 0 will represent either the absence of 
cells or cells have not yet adhered to the well bottom. This value increases as the cells begin 
to adhere and also with change in cell status such as cell morphology, adhesion or viability. 
Figure 1.5 shows a diagrammatic representation of change in the cell index over a period of 
time before and after addition of the compound  
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Figure 1.5: Compound mediated cytotoxicity and its effect on cell index (CI) 
Cells are seeded in an E-plate™ and put in an RTCA SP station which is placed inside an incubator 
maintained at 37°C (10% CO2). Background impedance measurement is taken in part A followed by 
addition of cell suspension (1) and allowing the cells to grow for 24 h as depicted by part B. The test 
compound is added after 24 h (2) and the change in impedance is measured for the next few days 
(3). Different compounds have different effects on the cell morphology and viability. Some compounds 
will have no effect or rather aid in cell proliferation (C) causing an increase in CI or they could either 
be cytostatic or cytotoxic leading to drop in CI as shown by part D (Xing_JZ et al., 2006). 
 
The xCELLigence system provides us with a platform to monitor live cell behaviour in real 
time in a non-invasive way over the entire course of experiment, including cell attachment, 
spreading, proliferation and any treatment with compounds. Because of the real-time nature 
of the data acquisition, cellular manipulations and treatments can be performed. Due to 
kinetic nature of this method, both short-term and long-term cellular responses to a particular 
treatment can be monitored in order to rule out off-target effects. Hence, impedance readout 
for each treatment leads us to unique cellular response profiles, which can prove to be 
predictive in terms of mechanism of action (Atienza et al., 2006). 
In our approach we have studied change in CI upon treatment of cells with small molecules 
over a period of time. The cells treated with reference compound (drugs with known 
mechanism) showed a particular impedance curve pattern characteristic of their mode of 
action. When compared to test compound impedance this pattern provided us with hints 
about their mechanism.  
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1.3 Elucidation of mode-of-action 
To increase the likelihood of drug success and reducing the attrition rate, clear 
understanding of the drug’s mechanism is crucial. According to the US food and drug 
administration (FDA), only 8% of the drugs entering the phase of clinical trial are eventually 
approved. An investigational drug against Alzheimer, dimebon entered phase 2 of clinical 
trial based on several studies showing different mechanism but none showed a clear picture 
as to how exactly the drug worked. However, later companies like Pfizer and Medivation 
announced that the drug did not develop cognitive ability in phase 3 trial, which was the 
basis on which it was selected at the first place for further trial (Editorial, 2010). 
Understanding a drug’s mechanism not only reduces later stage failure but also enables 
better dosing through monitoring a drug’s effect on the target pathway and stratifying clinical 
trials to focus on those patients who are more likely to respond.  
Even when the mechanism is known, it is often difficult to predict side effects. Nevertheless, 
in a long run, mechanistic knowledge of the drug is worthwhile to increase the chances of 
drug approval, saving money, time and most importantly, the lives of patients (Editorial, 
2010). 
1.3.1 PI3K pathway effectors 
The phosphatidylinositol 3-kinase (PI3K) pathway has been conserved evolutionarily from 
yeasts to mammals (Chalhoub and Baker, 2009). This pathway became the prime focus in 
mid-1980s, when it became apparent that PI3K activity was physically and functionally 
associated with transforming activity of viral oncogenes, such as polyomavirus (Vivanco and 
Sawyers, 2002). 
PI3Ks are a family of intracellular lipid kinases that phosphorylate the 3’-hydroxyl group of 
phosphatidylinositols (PI) and phosphoinositides (Chalhoub and Baker, 2009). PI3Ks are 
grouped into three classes (I-III) according to their substrate preference, sequence 
homology, structure and function. Due to relevance to the project only class I have been 
described here. 
Class I PI3Ks: Class I PI3Ks are divided into two sub-families, depending on the receptors 
to which they couple. Class IA PI3Ks primarily phosphorylates inositol-containing lipids, 
known as phosphatidylinositols (PtdIns) at their 3’ position (Figure 1.6). The primary in vivo 
substrate is PtdIns (4, 5) P2 (hereafter called PIP2), which is converted to PtdIns (3, 4, 5) P3 
(called PIP3) (Vivanco and Sawyers, 2002). Members of Class IA are heterodimers of a 
regulatory subunit (with three isoforms: p85α, p85β and p55γ encoded by PI3KR1, PI3KR2 
and PI3KR3 genes respectively) and a p110 catalytic subunit (also with three isoforms 
p110α, p110β and p110δ encoded by PI3KCA, PI3KCB and PI3KCD genes, respectively). 
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Figure 1.6: PtdIns (4, 5) P2 to PtdIns (3, 4, 5 cycle 
Phosphatidylinositol phosphates are composed of a membrane-associated phosphatidic acid group 
and a glycerol moiety which is linked to a cytosolic phosphorylated inositol head group. 
Phosphatidylinositol 3-kinase (PI3K) can phosphorylate PtdIns (4, 5) P2 (PIP2) at the D3 position to 
form a second messenger PtdIns (3, 4, and 5)P3 (PIP3). Dephosphorylation of PIP3 to regenerate PIP2 
is accomplished by the 3’-phosphatase PTEN. Additionally, PIP3 can also be dephosphorylated at the 
D5 position by SHIP1 or SHIP2 to generate PIP2, another potential second messenger (Vivanco and 
Sawyers, 2002). 
The class IA p85 regulatory isoforms have a common core structure consisting of a p110-
binding domain (also called the inter-SH2 domain) (Figure 1.7) flanked by two Src-homology 
2 (SH2) domain. The longer isoforms, p85α and p85β, also have an extended N-terminal 
region (dashed outline) containing a Src-homology 3 (SH3) domain and a BCR homology 
(BH) domain flanked by two proline-rich (P) regions. 
The p110 catalytic domain consists of an N-terminal p85 binding domain that interacts with 
the p85 regulatory subunit, a Ras-binding domain (RBD) that mediates activation of the 
small GTPase Ras, a C2 domain, a phosphatidylinositol kinase homology (PIK) domain and 
a C-terminal catalytic domain (Engelman et al., 2006; Jiang and Liu, 2009). 
 
Figure 1.7: Classification of phosphatidylinositol 3-kinase (PI3K) family members (Engelman et 
al., 2006) 
In terms of substrate specificity, in vivo, class I PI3Ks primarily generate PIP3 from PIP2, 
whereas class III PI3Ks generate phosphatidylinositol 3-phosphate (PI-3-P) from PI. Class II 
PI3Ks preferentially generate PI-3-P and phosphatidylinositol-3,4-bisphosphate (PI-3,4-P2) in 
vitro, and might generate PI-3-P, PI-3,4 P2 and possibly PIP3 in vivo (Engelman et al., 2006). 
1.3.1.1 Activation and regulation of PI3K 
Extensive knowledge regarding PI3K activation and regulation has come from genetic 
studies in Caenorhabditis elegans and Drosophila melanogaster, both of which have a single 
class IA PI3K controlling growth and metabolism. Although this knowledge has increased our 
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understanding but PI3K activation and regulation is more complex in mammals due to 
multiple family members of the PI3K signalling pathway.  
Relatively little is known about the specific functions of class II and III PI3Ks. Commonly 
used PI3K inhibitors, wortmannin and LY294002, inhibit class I and III PI3Ks and to a lesser 
extent class II PI3Ks. This lack of class specificity increases the importance of developing 
isoform-specific small molecule inhibitors which would also help in clarifying distinct cellular 
functions of different PI3Ks (Engelman et al., 2006). 
Although signalling through all classes of PI3K is connected to key growth-regulatory 
processes, so far a key role in cancer has been demonstrated selectively for class IA PI3Ks 
(Chalhoub and Baker, 2009). 
p85 is directly associated with many active tyrosine kinases (e.g., PDGFR [platelet-derived 
growth factor receptors], EGFR [epidermal growth factor receptors] etc.) (Mellor et al., 2012) 
through physical interaction of its SH2 domain with phosphotyrosine residue in the context of 
a YXXM consensus sequence on the kinase (Figure 1.8). In some cases, the p85-RTK 
interaction is indirect and occurs through intermediate phosphoproteins, such as the insulin 
receptor substrates IRS1 and IRS2. In response to extracellular cues class IA PI3Ks 
catalyse the formation of PIP3 from PIP2. PIP3 transduces activating signals by binding to 
proteins having pleckstrin homology (PH) domains like Akt (protein kinase B) and PDK1 (3-
phosphoinositide-dependent kinase 1), thereby recruiting them to the membrane (Chalhoub 
and Baker, 2009). 
 
Figure 1.8: Model of PI3K activation 
Autophosphorylation of ligand-activated receptor tyrosine kinases (RTKs) causes recruitment of the 
inactive heterodimeric class IA PI3Ks through interaction of phosphotyrosine residues on the receptor 
and SRC-homology 2 (SH2) domains on the PI3K p85 regulatory subunit, or the adaptor proteins 
IRS1 and IRS2. Phosphorylation of IRS1 and IRS2 generates docking site for SH2 domains of p85 
inducing proper assembly of the signalling complex. These SH2-phosphotyrosine interactions bring 
PI3K in close proximity to its substrate PIP2 at the plasma membrane to convert it to PIP3 (Vivanco 
and Sawyers, 2002). 
Once recruited to the plasma membrane PH-domain containing serine/threonine kinase 
named PDK1 phosphorylates Akt on Thr308. Phosphorylation at Thr308 is necessary and 
sufficient for Akt activation; however, maximal activation requires additional phosphorylation 
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at Ser473 by PDK2, a kinase characterized biochemically but its molecular identity still 
remains undetermined. Akt is activated by a dual regulatory mechanism that requires both 
recruitment to plasma membrane and phosphorylation by PDKs at Thr308 and Ser473 
(Vivanco and Sawyers, 2002).  
Upon Akt activation, (Figure 1.9) biological consequences could be categorized into survival, 
proliferation and growth (Liang and Slingerland, 2003). Akt functions in an anti-apoptotic 
pathway by phosphorylating several components of the cell-death machinery, e.g., BAD, a 
pro-apoptotic member of the BCL2 family of proteins, thereby inhibiting the catalytic activity 
of the pro-death protease, caspase-9. Akt can also influence cell survival by indirect effects 
on two central regulators of cell death – nuclear factor κB (NF-κB) and p53 (Vivanco and 
Sawyers, 2002). Upon phosphorylation of mouse double minute 2 (Mdm2) by Akt, it is 
translocated into the nucleus where it binds with p53. Mdm2 ligates ubiquitin to p53 which 
targets it for degradation by proteasome (Mayo and Donner, 2002). Akt can also affect 
proliferation through signalling cell cycle machinery components like cyclin D1 etc. 
Proliferation refers to cell division, which leads to an increase in cell number, whereas 
growth refers to the synthesis of macromolecules, which results in increased cell mass or 
size. Therapeutic targeting of the PI3K pathway is being developed at a rapid pace 
(Courtney et al., 2010). Pharmacological studies with the inhibitor rapamycin indicate that 
the Akt pathway regulates mTOR (Vivanco and Sawyers, 2002). 
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Figure 1.9: PI3K signalling and downstream activation of various proteins 
Activation of class IA PI3K occurs through stimulation of RTKs leading to assembly of receptor-PI3K 
complex. This complex localizes at the membrane where PIP2 is converted to PIP3 by p110 catalytic 
unit of PI3K. PIP3 serves as second messenger activating PH domain containing proteins like Akt and 
PDK1. Through Akt phosphorylation, activation and inhibition of several target takes places resulting 
in cellular growth, survival and proliferation. Additionally, PI3K has been shown to regulate the activity 
of other cellular targets like the serum and glucocorticoid-inducible kinase (SGK), the small GTP-
binding proteins RAC1 and CDC42, and protein kinase C, in an Akt-independent manner through a 
poorly characterised mechanism. The activity of these target leads to survival, cytoskeletal 
rearrangement and transformation. GSK3β, glycogen synthase kinase-3β (Adapted from (Vivanco 
and Sawyers, 2002)). 
The popular use of the phrase “PI3K-Akt pathway” in scientific literature shows that Akt is a 
crucial downstream target of PI3K. But Akt is not the only effector protein because PI3K and 
PIP3 can activate a growing list of signalling pathway (Figure 1.9), many of which are 
consistent with oncogenesis, e.g., activation of small GTP-binding proteins CDC42/RAC1 
and activation of the serum and glucocorticoid-inducible kinase (SGK). CDC42 and RAC1 
are best known for their role in regulating cytoskeletal movement and cell motility, and can 
function as oncogenes in fibroblasts when overexpressed.  
The serum and glucocorticoid-inducible kinase (SGK) family has attracted recent attention 
because of their high homology to Akt and similar functional effects on survival pathways. 
The SGKs encode serine/threonine kinases that can be activated by IGF1 (Insulin growth 
factor-1) and other stimuli in a PI3K-dependent manner (Figure 1.9) (Vivanco and Sawyers, 
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2002). There are three isoforms of SGK, namely SGK1, SGK2 and SGK3 with similar 
substrate specificity to Akt (Bruhn et al., 2013). The amino acid sequences of the three 
isoforms are 80% identical with one another in the catalytic domain whereas the short C-
terminal non-catalytic domain is less similar (44-68% identity). They also vary in their tissue 
distribution pattern and response to serum activation. SGK is activated by phosphorylation at 
Thr256 by PDK1 in vitro and phosphorylation is greatly enhanced by the mutation of Ser422 to 
Asp (Kobayashi and Cohen, 1999; Kobayashi et al., 1999; Park et al., 1999). Due to lack of 
literature information on other isoforms, only SGK1 will be discussed in section 1.3.1.4. 
PI3K is tightly regulated in normal cells both at regulatory and catalytic activity levels. SH3 
and BCR domains of p85 regulatory unit are postulated to have negative regulatory role 
towards p110 catalytic unit and these two domains are absent in the splice variants of p85α-
p55α and p50α. (Figure 1.7) This is consistent with the observation that both p55α and p50α 
are efficient activators of p110 than p85α. A pre-formed, inactive p85-p110 complex is 
present in the cytoplasm of resting cells, waiting to be activated upon appropriate cues. PI3K 
becomes active when the p110 catalytic subunit is in close proximity to its lipid substrates in 
the plasma membrane and also by interaction between RTKs and p85 relieving the inhibitory 
effect of p85 on p110 kinase activity due to conformational change in the p85-p110 complex. 
Regulation is not only carried out at the kinase level but also with the levels of PIP3. PIP3 is 
barely detectable in mammalian cells under unstimulated growth conditions. Several PIP3 
phosphatases (PTEN, SHIP1 and SHIP2) ensure optimum levels of PIP3. PTEN, a 3’ lipid 
phosphatase converts PIP3 back to PIP2. Its function and regulation will be discussed in 
detail in section 1.3.1.2. SHIP (SH2-domain containing inositol 5-phosphate) also acts on 
PIP3 but removes phosphate from the 5’ position rather than 3’, forming PI (3, 4) P2, another 
second messenger. PI (3, 4) P2 also recruits Akt at the plasma membrane and reduces the 
levels of PIP3. However PTEN, unlike SHIP1 gives a strong cancer phenotype in mice. In 
addition, SHIP1-knockout mice have shown to develop myeloproliferative syndromes, 
indicating that PI (3, 4)P2 can activate certain mitogenic pathways (Sulis, 2003; Vivanco and 
Sawyers, 2002). 
1.3.1.2 PTEN phosphatases 
The PTEN (phosphatase and tensin homologue deleted on chromosome 10) lipid 
phosphatase is the most important negative regulator of PI3K signalling pathway (Cully et 
al., 2006). PTEN antagonizes the PI3K signalling pathway by dephosphorylating the 3’ 
position of the inositol ring of PIP3 (Leslie and Downes, 2002) and thus inactivating 
downstream signalling which ultimately stops cell proliferation. (Figure 1.10) PTEN is tumour 
suppressor (Hafsi et al., 2012) located at 10q23 (GenBank accession number AF067844) 
(Stambolic et al., 2001), also named as “mutated in multiple advanced cancers” (MMAC) and 
“TGF-β-regulated and epithelial cell-enriched phosphatase” (TEP-1) (Cantley and Neel, 
1999). It was identified to be frequently mutated/deleted in various human cancers (Freeman 
et al., 2003). Non-phosphorylated form of PTEN is the active form which acts against the 
PI3K pathway (Rabinovsky et al., 2009). 
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Figure 1.10: Interconnections between PI3K-Akt pathway and p53 involving PTEN 
p53 negatively regulates Akt and mTOR pathway through upregulation of PTEN in response to stress. 
Akt-Mdm2-p53 forms a negative feedback loop to negatively regulate p53, whereas p53-PTEN-Akt-
Mdm2 forms a loop to positively regulate p53. PI3K converts PIP2 to PIP3 which in turn recruits PH-
domain containing proteins like Akt and PDK1 and 2 to plasma membrane to phosphorylate 
downstream protein which aid in cell growth and survival. On the other hand PTEN converts PIP3 to 
PIP2 thereby acting against PI3K pathway (Adapted from (Feng, 2010). 
 
Structure: PTEN is a 403-amino-acid protein (Figure 1.11) and a member of the large PTP 
family (protein tyrosine phosphatase) (Leslie and Downes, 2004). It reveals a phosphatase 
domain similar to that of protein phosphatases but has an enlarged active site important for 
accommodation of PI. The PTEN C2 domain binds to the phospholipid membrane in vitro, 
and mutation of basic residues that could mediate membrane recruitment reduces PTEN’s 
membrane affinity and its ability to suppress the growth of glioblastoma tumour cells. 
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Figure 1.11: The PTEN protein 
The PTEN protein consists of 403-amino-acid. The N-terminal phosphatase domain (amino acid 7-
185) and the C2 domain (186-351) are both required for enzymatic activity. The catalytic cysteine 
residue (Cys-71 & 124) forms a disulphide bond when the enzyme is oxidized. It is still not clear 
whether in a cell PIP2 motif responds to PIP2 or to more acidic lipid such as phosphatidylserine. The 
PDZ binding domain at the C-terminal end is represented by a small region whose function is still not 
clear. The phosphorylation sites in the C-terminal tail are represented by a circled letter P (Lee et al., 
1999). 
PTEN can dephosphorylate tyrosine, serine and threonine-phosphorylated peptides. This 
activity requires highly acidic substrate which is fulfilled by PIP3. Tumour-derived mutation 
spreads evenly to the two domains, and mutations in either reduces or eliminates PTEN’s 
growth suppression activity (Das et al., 2003; Lee et al., 1999). 
Regulation: Unlike several signalling enzymes, PTEN lacks a regulatory domain and 
appears to have relatively high constitutive phosphatase activity, both in vitro and in cells. 
Studies have shown that PTEN can be regulated by phosphorylation, membrane recruitment 
and oxidation (Tamguney and Stokoe, 2007). Phosphorylation of a cluster of serine and 
threonine residues (Ser370, Ser380, Thr382, Thr383 and Ser385) on PTEN induces a 
conformational switch whereas de-phosphorylation makes  PTEN highly susceptible to 
proteolysis, increases its affinity for anionic lipids and enhances its localization to the plasma 
membrane (Leslie and Downes, 2004). 
PDZ binding site Phosphorylation sites 
PIP2 binding site 
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Figure 1.12: PTEN regulation by phosphorylation 
Phosphorylated residues in the C-terminal tail of PTEN interact with the basic regions of the 
phosphatase (Phos) and C2 domain, causing masking of the basic membrane-binding surface of 
PTEN by C-terminal tail. This causes PTEN to remain in the cytosol and away from PIP3. 
Dephosphorylation of these residues releases the C-terminal tail, allowing the electrostatic interaction 
of both the domains with acidic membranes (Leslie and Downes, 2004). 
PTEN is highly sensitive to oxidation, with a disulphide bond being formed between the 
active-site cysteine Cys124 and Cys71. Oxidation could be both due to experimental oxidative 
stress and by endogenous production of reactive oxygen species which could lead to 
PTEN’s inactivation (Leslie and Downes, 2004). 
1.3.1.3 PTEN inactivation in tumours 
Mutations in various kinds of sporadic tumours and tumour cell lines first showcased the 
involvement of the PTEN gene. The classical view has been that tumour suppressor genes 
are recessive, such that both the allele should be lost for a tumour to develop but in case of 
PTEN partial loss or haplo-insufficiency gives a selective advantage to the tumour cells 
(Leslie and Downes, 2004). Knock-out mice lacking PTEN are embryonic lethal, whereas 
mice with one copy of PTEN have diminished Fas-mediated apoptosis and a high incidence 
of cancer. (Campbell et al., 2003). PTEN mutation is most prominently found in advanced 
glial tumours (at least 30% of primary tumours and 50-60% of cell lines) but also prostate, 
endometrial, renal and small-cell lung carcinoma. Germ-line mutations in PTEN cause rare 
autosomal dominant inherited cancer syndromes namely Cowden disease, Lhermitte–
Duclos disease and Bannayan–Zonana syndrome (Cantley and Neel, 1999; Sansal and 
Sellers, 2004). Several mechanisms have come to light with regards to the PTEN 
inactivation which includes mutation in the coding sequence of PTEN, loss of heterozygosity 
(LOH) and loss of expression of PTEN protein (Leslie and Downes, 2004). 
Mutations within the coding sequence mostly inactivate the phosphatase activity of the 
encoded enzyme. The majority of PTEN mutations in sporadic tumours and possibly all 
mutations in PTEN-associated inherited conditions fall in this category of loss of enzyme 
activity. However, there are other forms of tumour, too which have a strong phosphatase 
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activity but are still not able to suppress the tumour development indicating that the tumour 
suppressive activity is not entirely dependent on phosphatase activity. Mutation in the C-
terminal tail mostly does not affect the enzymatic activity but affects the protein stability. 
Breast and lung tumours show another mechanism of loss of heterozygosity. 
Immunohistochemical analysis suggests that in many tumours, one PTEN allele is deleted, 
and although these tumours retain one copy of PTEN with no detectable defect, expression 
of PTEN is lost (Leslie and Downes, 2004). 
All the above description provides us with evidence of PTEN to be a potent anticancer target 
in tumours in which for some reason PTEN becomes inactive or not produced in adequate 
amounts. 
1.3.1.4 Serum and glucocorticoid-inducible kinase 1 (SGK1) 
SGK1 was originally cloned as a gene transcriptionally stimulated by serum and 
glucocorticoids in rat mammary tumour cells. The human SGK1 was discovered as a cell 
volume regulated gene upregulated by cell shrinkage. SGK1 is ubiquitously expressed. The 
gene encoding human SGK1 is localized to chromosome 6q23. SGK1 participates in the 
regulation of transport, hormone release, neuroexcitability, inflammation, cell proliferation 
and apoptosis by activating a variety of ion channels, regulation of enzymes like GSK3 and 
transcription factors. 
Proliferative signals help in shuttling of SGK1 into the nucleus thereby activating it (Firestone 
et al., 2003). PI3K pathway converts PIP2 to PIP3 which causes phosphorylation and 
activation of SGK1 by PDK1 at Thr256 within the activation loop of SGK1 and Ser422 in C-
terminal domain, presumably by PDK1-like enzyme (Firestone et al., 2003) (Figure 1.9). In 
terms of structure, SGK has a catalytic domain homologous to Akt (54% identity), but lacks 
the PH domain unlike Akt (Lang and Cohen, 2001; Sakoda et al., 2003). SGK1 modifies cell 
survival by phosphorylating Mdm2 thus enhancing Mdm2-dependent p53 ubiquitylation with 
subsequent proteosomal p53 degradation. Like in case of Akt, SGK1 also has an Mdm2-p53 
autoregulatory loop. 
SGK1 is upregulated in several tumours. It mediates the glucocorticoids induced resistance 
of breast cancer cells to chemotherapy (Lang et al., 2009; Lang et al., 2006). Stimulation of 
amino acid, peptide, creatine and glucose transport by SGK1 meets the excessive demand 
of rapidly growing tumour cells.  
Downregulation of SGK1 is seen in case of prostate cancer, ovarian tumour and 
hepatocellular carcinoma; presumably SGK1-dependent functions are taken up by other 
SGK isoform and Akt. 
Taken together the available evidence indicating the role of SGK1 contribution towards 
tumour development and progression, it forms a potential target for tumour therapy (Lang et 
al., 2010). 
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1.4 Bioactive small molecules 
As described earlier nature provides us with range of bioactive molecules which not only are 
important for the survival of the producer but can also be used by other organisms to fight 
against various invasions like bacterial or fungal infection. Knowing a small molecule is 
biologically active is as important as knowing its mechanism to utilize its full potential. 
Therefore, selected compounds were investigated in this study, in terms of their bioactivity 
towards their mode of action. 
1.4.1 Jerantinine E 
Indole alkaloids with fascinating structural features have not only attracted synthetic chemist 
but also biologist because of their remarkable bioactivity. Best representation for this 
particular group of compound is vinblastine. But due to difficulty in de novo synthesis of 
novel vinblastine analogues, much simpler anti-cancer agents were looked for, e.g., new 
Aspidosperma alkaloids which were originally isolated from Aspidosperma trees. Seven new 
Aspidosperma indole alkaloids, jerantinine A–G were reported by Kam and co-workers in 
2008. These were isolated from leaf extracts of Malayan plant Tabernaemontana corymbosa 
(Figure 1.13) which has a widespread distribution in pantropical regions (Frei et al., 2013; 
Lim et al., 2008). 
One of these jerantinine E (Figure 1.13) displayed significant cytotoxic activity against 
human cervix carcinoma cells (KB-3-1) which is rare among Aspidosperma alkaloids 
 
Figure 1.13: Structure of jerantinine E and its source, Tabernaemontana corymbosa 
Jerantinine E showed cytotoxicity against vincristine-sensitive (IC50=2.55 µM) and 
vincristine-resistant (IC50=2.03 µM) epidermoid carcinoma cell lines compared to 0.0054 µM 
and 1.2 µM by vincristine respectively (Lim et al., 2008). The mode of action for the 
cytotoxicity was not known. The availability of a significant amount of synthesised jerantinine 
E allowed us to investigate in this direction. 
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1.4.2 Paleo-soraphen A and B 
Polyketides derived from fungi and bacteria have been in focus of both chemical and 
biological investigations. The biosynthesis of polyketides follows a modular linear assembly 
of various enzymes whose genetic analysis can not only be used to rationalize its 
biosynthesis but also to predict the stereochemical outcome. However deviating from the 
norms of modular synthesis, most of the polyketide synthases show at least one enzymatic 
step to be non-productive. Whether this is a consequence of an evolutionary process or the 
chemical consequence of the substrate is still unknown (Lu et al., 2013). 
Soraphens were discovered in the myxobacterium Sorangium cellulosum in 1994 (Gerth et 
al., 1994) and found to be strong inhibitors of the eukaryotic acetyl-coenzyme A carboxylase 
(ACC). Investigation on the biosynthetic origin identified two positions of the isolated natural 
product that differed from the genetically expected outcome (Schupp et al., 1995; Wenzel et 
al., 2006). The compounds that would be expected were prepared synthetically. These 
compounds were called paleo-soraphen A & B, which are derivatives of soraphen obtained 
from following the complete intact modular assembly of its polyketide synthases. These were 
studied to see if and how their biological behaviour is changed. Structurally, a double bond is 
expected between the C2 and C3 position established by module 8 but is missing in 
soraphen A due to the inactivity of the dehydratase activity within that domain. (Figure 1.14) 
There is still a double bond between C9 and C10 which is absent in case of paleo-soraphen 
B and is proposed to be due to postketide transformations and not a direct consequence of 
PKS (Lu et al., 2013). 
 
Figure 1.14: Structure of soraphen A and synthetic polyketides derived from genetic analysis 
(Lu et al., 2013) 
Soraphen A showed antifungal activity, therefore we wanted to study if this activity is still 
maintained in its derivatives or has acquired a totally different target. 
1.4.3 Disorazols 
Disorazols, forming a new class of microtubule disrupting macrodiolides, were isolated from 
the fermentation broth of the myxobacterium Sorangium cellulosum strain So ce12 (Hopkins 
and Wipf, 2009). They comprise a family of 29 variants first isolated in 1994, exhibiting some 
of the highest cytotoxicities towards animal cells (IC50 for disorazol A1 = 1.6 pM against KB-
3-1 cervical carcinoma cells) 
paleo-soraphen B paleo-soraphen A soraphen A 
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1.4.3.1 Disorazol A1  
Disorazol A1 (Dsz A1) was identified as the major component, comprising 70% of the relative 
mass amount compared to the remaining 28 disorazols (Hopkins and Wipf, 2009) isolated 
from Sorangium cellulosum So ce12. Its structure was found to be a macrocyclic ring with 
two oxazole rings and an epoxide group (Figure 1.15) (Irschik et al., 1995). Dsz A1 shows 
exceptional subnanomolar activity against a panel of cancer cell lines. 
 
Figure 1.15: Structure of disorazol A1 (Dsz A1) and its myxobacterial source 
Dsz A1 is active against many filamentous fungi but not against yeast and bacteria (Irschik et 
al., 1995). To date Dsz A1 remains the most extensively studied member of the disorazol 
family due to its biological activity and mode of action. (Elnakady et al., 2004) demonstrated 
that the antimitotic effect of Dsz A1 originates from its tubulin polymerization inhibitory 
activity. They provided evidence that Dsz A1 acts in a concentration-dependent manner and 
independent of microtubule-associated proteins (MAPs), directly exerting its effect on tubulin 
during polymerization. Immunofluorescence staining showed that at lower concentrations (13 
pM) interphase microtubules were not impaired but a nuclear fragmentation was detectable 
whereas at higher concentration (>100 pM) the microtubular network was completely 
disrupted. Mitotic cells showed an abnormal spindle formation (Elnakady et al., 2004). 
Treatment with Dsz A1 causes a cell cycle arrest at G2/M checkpoint triggering apoptotic cell 
death cascade (Hopkins and Wipf, 2009). Dsz A1 has a high inhibitory effect even against 
the multi-drug resistant cell line KB-V1 expressing high Pgp levels. Enhanced Pgp levels 
causes enhanced drug efflux and reduce drug accumulation which is a leading cause for 
resistance shown towards paclitaxel or Vinca alkaloids. 
Immunofluorescence staining showed a nuclear localization of the tumour suppressor 
protein p53 (Elnakady et al., 2004) at lower concentrations of Dsz A1. Though the 
microtubular network was not altered much at low concentration, its dynamics could be 
suppressed enhancing the trafficking of p53 towards the nucleus. Paclitaxel and vincristine 
have also shown similar effect of p53 nuclear trafficking at a concentration lower than what is 
required for effecting tubulin polymerization (Chumakov, 2000; Giannakakou et al., 2002). To 
investigate the role of p53 translocation upon Dsz A1 treatment, its mode of action was 
studied in more detail. 
1.4.3.2 Disorazol Z 
Disorazol Z (Dsz Z, Figure 1.16) is produced by fermentation of the myxobacterium 
Sorangium cellulosum So ce1875. It shows potent inhibition of tumour cell lines (IC50 = 1.3 
nM in KB/HeLa cells) (Guenther et al., 2013). 
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Figure 1.16: Structure of disorazol Z (Dsz Z) 
With human Gonadotropin releasing hormone (GnRH receptor [hGnRH-R]) positive cells, a 
dose-dependent inhibition of cell proliferation in presence of Dsz Z was observed unlike in 
case of hGnRH-R negative cells. This effect was not only receptor-mediated but its anti-
proliferative efficacy was heightened by administering a conjugate of Dsz Z with [D-Lys6]-
LHRH (luteinizing hormone-releasing hormone). On the other hand only a moderate 
suppression of tumour growth was observed by using unconjugated Dsz Z (Guenther et al., 
2013). A variety of tumours, including breast, ovarian and prostate express receptors for 
LHRH (also regarded as GnRH) which can increase the chances of targeting such tumours 
by directing these cytotoxic agents by covalently binding them to an LHRH agonist peptide. 
This conjugate when internalized into the cell will release the cytotoxic agent upon hydrolysis 
(Weissman and Muller, 2010). The bioactivity and detailed mode of action was also 
investigated during this study. 
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1.5 Aim of the project 
Historically nature has been an important source of compounds, with knowledge of its toxic 
or medicinal properties often long predating knowledge of its precise target or mechanism 
(Schenone et al., 2013). High content methods can be used for both screening and profiling 
bioactive compounds to obtain hints about their mode of action by comparing them with 
compounds of known mechanism. 
The study presented made use of high content analysis profiling to investigate the mode of 
action of selected compounds. Automated microscopy, a labelled cell-based profiling method 
formed the basis for further studies of their mechanisms along with a label-free non-invasive 
detection method – xCELLigence, which is based on impedance profiling. Our aim was to 
gain insights into the mode of action or at least to know the affected pathway for jerantinine 
E, an alkaloid, polyketides like paleo-soraphen A & B and two members of the disorazol 
family. The approaches utilized helped narrowing down the target search and follow-up 
studies have corroborated the hypothesis and elucidated their details.  
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2 Materials and methods 
2.1 Materials 
2.1.1 Equipment 
Automated microscope  ImageXpress® Micro (Molecular Devices) 
Cell counter    Cedex XS (Innovatis) 
Cell culture incubator   CO2-Auto-Zero (Heraeus) 
Centrifuges    Biofuge (Heraeus) 
     5810R (Eppendorf) 
     5418R (Eppendorf) 
Fluorescence microscope  Axioplan with Axiocam camera (Zeiss) 
Gel electrophoresis system  Mini PROTEAN system (Bio-Rad) 
Laminar airflow   Maxisafe 2020 (Thermo Fisher Scientific) 
Microplate washer   405 Select TS (Biotek) 
Plate reader    Infinite M200 pro (Tecan) 
Robot pipette with pintool  Biomek FXP Laboratory Automation Workstation 
(Beckman Coulter) 
Semi-dry transfer system  Trans-Blot® SD (Bio-Rad) 
Shaker     Titramax 1000 (Heidolph) 
xCELLigence incubator  MIDI 40, CO2 incubator (Thermo Fisher Scientific) 
xCELLigence RTCA system  RTCA SP (Acea Biosciences) 
X-ray processor   Optimax (ClassicXray) 
2.1.2 Software 
AcuityXpress™ 2.1.0.2, Autodock 4.0, AxioVision 4.8, Cedex XS software, ChemDraw Std 
12.0, GelQuantNET 1.8.2, i-Control™, ImageJ, MetaXpress 2.0.0.13, Microsoft Office 2010, 
R, RTCA software 1.2, SigmaPlot 12.3. 
2.1.3 Consumables 
All consumables were purchased from Becton Dickinson, Eppendorf, Greiner, Macherey-
Nagel, Nunc, Thermo Fisher Scientific, TPP or Roth, unless otherwise stated. For high 
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content analysis, microtitre plates were obtained from Corning (384 well) and E-plate (96 
well) for xCELLigence from Roche/Acea Biosciences. 
2.1.4 Chemicals 
All chemicals were obtained from Alexis Biochemicals, Bayer, Becton Dickinson, Fluka, 
Gibco, Invitrogen, JT Baker, Merck, Roche Diagnostics, Serva, Thermo Fisher Scientific, 
Roth or Sigma. 
2.1.5 Antibodies/ Dyes 
Anti-akt antibody (rabbit) Cell Signaling 
Anti-anillin (rabbit) Bethyl Laboratories 
Anti-calmodulin (mouse) Invitrogen 
Monoclonal anti-Pan Cytokeratin, Clone C-11 (mouse) Sigma 
Anti-c-Fos (rabbit) Sigma 
DAPI dihydrochloride  Sigma 
Monoclonal GAPDH (HRP conjugate) (rabbit) Cell Signaling 
Anti-GRP94 (rat) Sigma  
Monoclonal anti-p53, Clone BP53-12 (mouse) Sigma 
Polyclonal anti-PI3 Kinase p110 (rabbit) Cell Signaling 
Polyclonal anti-PI3 Kinase p85 (rabbit) Cell Signaling 
Monoclonal anti-PTEN (D4.3) XP™ (rabbit) Cell Signaling 
Anti-PDK1 Cell Signaling 
Monoclonal anti-Splicing Factor SC-35, Clone SC-35 (mouse) Sigma 
Trypan blue solution Roche 
Monoclonal anti-α-Tubulin, Clone B-5-1-2 (HCA),DM1A (mouse) Sigma 
Phospho-Akt (Ser473) (rabbit) Cell Signaling 
Phospho-CREB (rabbit) Sigma 
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Phospho-p53 (Ser15) (rabbit) Cell Signaling 
Phospho-PDK1 (Ser241)(C49H2) (rabbit) Cell Signaling 
Phospho-p38 MAPK (Thr180/Tyr182) (rabbit) New England Biolabs 
Phospho-p44/42 MAPK (Thr202/Tyr204) (mouse) New England Biolabs 
Phospho-PI3K p85 (Tyr458)/p55 (Tyr199) (rabbit) Cell Signaling 
Phospho-p53 (Ser315) (rabbit) Santa Cruz 
Phospho-SGK (Ser 422) (rabbit) Santa Cruz 
SignalSilence® Control siRNA (Fluorescein conjugate) Cell Signaling 
SignalSilence® PI3 Kinase p85α siRNA I (mouse) Cell Signaling 
SignalSilence® PTEN siRNA II Cell Signaling 
Alexa Fluor 488 Phalloidin Molecular Probes 
Alexa Fluor 488 anti-rabbit (goat) Molecular Probes 
Alexa Fluor 549 anti-rabbit (goat) Molecular Probes 
Alexa Fluor 594 anti-mouse (goat) Molecular Probes 
Alexa Fluor 488 streptavidin Molecular Probes 
Alexa Fluor 488 anti-rat (rabbit) Invitrogen 
Anti-mouse (rabbit) Dianova 
Anti-rabbit (HRP-linked) Cell Signaling 
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2.1.6 Culture media 
The mammalian cell culture media used are listed in Table 2.1 
Table 2.1: Media used for different cell lines 
Cell line Medium Manufacturer Supplements 
A-549, L-929 MEM Gibco 10% FBS (Lonza) 
KB-3-1, A-431 DMEM Lonza 10% FBS (Gibco) 
PtK2 MEM Gibco 1X Non-essential amino acids (Gibco) 
1X GlutaMAX (Gibco) 
10% FBS (Lonza) 
PC-3 F-12 K Gibco 10% FBS (Gibco) 
MCF-7 DMEM Gibco 1X Non-essential amino acids (Gibco) 
1.5% Insulin (Gibco) 
10% FBS (Lonza) 
HUVEC EMB
®
-2 Lonza EMB
®
-2 bullet kit 
 
2.1.7 Buffers 
1. 10X SDS running buffer:  288 g glycine 
     60.4 g Tris Base 
     20 g SDS 
     2 L distilled water 
The buffer was diluted to 1X with distilled water to make working SDS running buffer. 
2. 10X TBS buffer for western blotting (pH: 7.0):  160 g NaCl 
        4 g KCl 
        12.2 g Tris Base 
        2 L distilled water 
The working TBS solution was prepared by diluting the 10X buffer to 1X with distilled water.  
TBST buffer was made by adding 1 mL Tween-20 to 1000 mL of 1X TBS buffer. 
3. 10X blotting buffer:   25 mM Tris HCl 
     192 mM Glycine 
The working blotting buffer was prepared by diluting 10X buffer to 1X with distilled water. 
2.1.8 Kits 
BCA protein assay kit      Thermo Fisher Scientific 
Caspase-Glo® 3/7 assay kit     Promega 
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Cell death detection ELISA PLUS kit    Roche 
MycoAlert ® Mycoplasma Detection Kit   Lonza 
SuperSignal® West Pico Luminol solution   Thermo Fisher Scientific 
SuperSignal® West Femto Luminol solution   Thermo Fisher Scientific 
2.1.9 Cell cultures 
Table 2.2: Mammalian cell lines 
Cell line Source Species Origin Morphology 
A-549 DSMZ ACC 107 Human Lung cancer Epithelium-like 
A-431 DSMZ ACC 91 Human Epidermal cancer Epithelium-like 
KB-3-1 DSMZ ACC 158 Human Cervical cancer Epithelium-like 
L-929 DSMZ ACC 2 Mouse Connective tissue Fibroblasts 
MCF-7 DSMZ ACC 115 Human Breast cancer Epithelium-like 
PtK2 ATCC CCL-56 Potoroo Kidney Epithelium-like 
PC-3 DSMZ ACC 465 Human Prostate cancer Epithelium-like 
HUVEC Lonza C2519 Human Umbilical vascular 
endothelium 
Cobblestone-like 
 
2.2 Methods 
2.2.1 Working with mammalian cell cultures 
2.2.1.1 Cultivation 
Work with mammalian cell cultures was performed under sterile condition of laminar hood. 
The required media were warmed at 37°C before using. The cells were kept in cell culture 
flasks at 37°C and 10% CO2. The media volume depended on the size of the cell culture 
flasks viz. 10 mL for 25 cm2 (T25), and 30 mL for 75 cm2 (T75) flasks. Adherent cells like L-
929 and KB-3-1 were harvested and passaged when they were semi-confluent (~ 80-90% 
confluency). The cell layer was scraped with a cell scraper from the bottom of the vessel and 
the cells were suspended by repeatedly pipetting up and down with a sterile disposable 
plastic pipette. Other cell lines like PtK2, A-549, A-431, PC-3, MCF-7 were trypsinised for 
passaging. To trypsinise the cells, the culture media was removed and the cell surface was 
rinsed once with EBSS. Cells were later incubated at room temperature under clean bench 
for one min or two with 1 mL of pre-warmed trypsin. Pre-warmed trypsin was discarded and 
the flask was incubated at 37°C for 5-13 minutes. The trypsinisation was stopped by adding 
fresh culture medium. The serum in the culture medium inactivates trypsin. Subsequently, an 
aliquot with different dilutions depending on the requirement was transferred to a new cell 
culture flask with fresh medium. The primary HUVECs were trypsinised for 2 min, and the 
reaction stopped by incubation with a trypsin stop solution at 37°C for 5 min. Fresh media 
was added to make cell suspension which was centrifuged at 1500 rpm for 5 min. The 
supernatant was discarded to ensure complete removal of trypsin and trypsin stop solution. 
Fresh media was added again to prepare a cell suspension. 
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All cell lines were maintained up to 1 year in culture except for HUVEC which is best to use 
within 5-6 passages. They were then discarded and a new culture from cryo-preserve was 
restarted. All cell cultures were semi-annually tested for mycoplasma using MycoAlert® 
detection kit according to the manufacturer’s protocol. 
2.2.1.2 Storage of cells 
For long term storage, the cells were harvested as for sub-culturing. They were then 
harvested by centrifugation (3000 rpm, 3 min), pelleted and re-suspended in 1 mL of 
freezing medium. They were transferred to cryo-tubes which were put into a freezing 
container (Nunc Cryo™ tube vials) at -70°C for at least 24 hours. After that the cells were 
maintained in a liquid nitrogen storage container at -196 ° C. 
To reactivate the cryo-preserved cells, the cells were quickly thawed at 37°C and seeded in 
10 mL of fresh medium in a T25 flask. After a day, the cell culture medium was changed to 
remove the freezing medium completely. 
2.2.2 MTT assay 
Anti-proliferative activity was measured in 96-well transparent plates. 60 µL of serially diluted 
compounds were added to 120 µL of suspended cells (50,000 cells/mL; duplicates). The end 
concentrations tested ranged from 37 µg/mL to 0.1 ng/mL. After five days of incubation with 
the compounds, the metabolic activity in each well was determined using an MTT (3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) reagent. 20 μL MTT in PBS were 
added to give a final concentration of 0.56 mg/mL and incubated for two hours. MTT is 
reduced by dehydrogenase of the cell to form purple formazan crystals. The precipitate was 
washed with 100 μL PBS and dissolved in 100 μL isopropanol containing 0.4 % hydrochloric 
acid. The resulting colour was measured at 595 nm using a plate reader. 
2.2.3 xCELLigence – High Content Analysis (HCA) 
2.2.3.1 Equipment/Software 
RTCA SP (Real Time Cell Analyser Single plate) instrument consisting of 
  RTCA analyser 
  RTCA SP station 
  E-plate 96 and  
  RTCA control unit 
  RTCA software 1.2.1 
  Software R version 2.12.2 
2.2.3.2 Impedance measurement 
Changes in impedance readings were measured over a period of five days. 60 µL of the cell 
media was added to both an E-plate and a normal micro titre plate (MTP) and left for half an 
hour under clean laminar hood to stabilise. Meanwhile cell suspension was prepared from L-
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929 cells at a dilution of 1, 00,000 cells/mL. After half an hour background measurement was 
taken by placing the E-plate on the RTCA SP station which is placed inside an incubator at 
37°C and 10% CO2. Later 120 µL of cell suspension was added to each well and left under 
the clean laminar hood for half an hour for homogenous distribution of cells. Later the plate 
was placed for impedance measurement for 24 h by clamping the plate in the station. The 
following day the E-plate was taken out of the incubator and 1 µL of test compounds at a 
concentration of IC90 or highest available concentrations were added under the clean laminar 
hood. Table 2.3 shows the reference compounds included used for the analysis. These 
reference compounds were added in triplicates and change in impedance was recorded. 
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Table 2.3: Library of reference compounds 
S. No. Name Mode of action Concentration in 
library (µM) 
S.No. Name Mode of action Concentration 
in library (µM) 
1. A23187 ion-carrier (e.g. calcium) 110 33. MG132 proteasome inhibitor 400 
2. Actinomycin D transcription inhibitor 4.4 34. Myriaporone inhibits protein synthesis 70 
3. Alsterpaullone CDK inhibitor 200 35. Myxothiazol A inhibits respiratory chain 12 
4. Amanitin blocks mRNA synthesis 1000 36. Neopeltolide inhibits respiratory chain 100 
5. Anisomycin inhibits protein synthesis 45 37. Nocodazole promotes microtubule depolymerisation 12 
6. Aphidicolin inhibits DNA-polymerase 1000 38. Okadaic acid inhibits Ser/Thr phosphatases 10 
7. Apicidin histone-deacetylase (HDAC) inhibitor 100 39. Oligomycin F-ATPase inhibitor 70 
8. Apicularen V-ATPase inhibitor 31 40. Oxamflatin histone-deacetylase (HDAC) inhibitor 1200 
9. Archazolid B V-ATPase inhibitor 3 41. PD169316 p38-MAP-Kinase inhibitor 10,000 
10. Argyrin A proteasome inhibitor 1000 42. PMA activates protein kinase C 3500 
11. Brefeldin A vesicle trafficking 50 43. Podophyllotoxin promotes microtubule polymerisation 2.5 
12. Camptothecin topoisomerase I inhibitor 450 44. Puromycin inhibits protein synthesis 500 
13. Chelerythrine protein kinase C inhibitor 1000 45. Purvalanol A CDK inhibitor 2000 
14. Chivosazole A actin polymerisation inhibitor 1.3 46. Rapamycin PI3-Kinase inhibitor 11 
15. Chondramid C stabilises actin filaments 10 47. Ratjadon C blocks nuclear receptor 3.5 
16. Colchicine inhibits microtubules 10 48. Rhizopodin A inhibits actin polymerisation 10 
17. Cruentaren A F-ATPase inhibitor 14 49. Saframycin Mx1 inhibits DNA synthesis 40 
18. Cycloheximide inhibits protein synthesis 450 50. SB202190 p38-MAP-Kinase inhibitor 10,000 
19. Cyclosporin A affects calcium regulation 5500 51. SB203580 p38-MAP-Kinase inhibitor 10,000 
20. Cytochalasin D promotes actin depolymerisation 100 52. Scriptaid histone-deacetylase (HDAC) inhibitor 4000 
21. Dexamethasone immunosuppressive effect 4500 53. Simvastatin inhibits cholesterol biosynthesis 800 
22. Doxorubicin topoisomerase II inhibitor 340 54. Soraphen A inhibits lipid synthesis 400 
23. Emetine inhibits protein synthesis 41 55. Staurosporine inhibits protein kinase 3 
24. Epothilone B stabilises microtubules 0.55 56. Taxol microtubule stabiliser 25 
25. Etoposide topoisomerase inhibitor 2300 57. Trichostatin histone-deacetylase (HDAC) inhibitor 310 
26. Gephyronic acid A inhibits protein translation 60 58. Tubulysin B inhibits microtubule polymerisation 0.4 
27. Griseofulvin inhibits spindle apparatus 10,000 59. Tunicamycin glycoprotein synthesis 700 
28. H89 protein kinase A inhibitor 10,000 60. Velcade proteasome inhibitor 11 
29. Indirubin-3'-monoxime CDK inhibitor 8000 61.. Vinblastin inhibits microtubule polymerisation 0.5 
30. LY294002 PI3-Kinase inhibitor 10,000 62. Vioprolid A PI3 Kinase inhibitor 7 
31. Methotrexate inhibits DNA synthesis 50 63. Wortmannin PI3-Kinase inhibitor 10,000 
32. Mevastatin inhibits cholesterol biosynthesis 1200     
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The E-plate also had wells with DMSO or methanol added to it as a solvent control and it 
was ensured that its concentration did not exceed 0.1% DMSO or methanol. The same set 
of test compounds were added to the normal MTP and returned to the incubator at 37°C. 
The test compounds were done in triplicates and randomly distributed all over the E-plate to 
avoid batch affects. The E-plate was returned to the incubator and the impedance read over 
the span of four days. The comparative MTP was used for microscopic evaluation. 
2.2.3.3 Analysis 
The time-dependent cellular response profiles (TCRP) were recorded by Roche RTCA 
software. Data processing and mining workflow was implemented in the statistical 
programming language R, Version 2.12.2 (R Development Core Team, 2011). The analysis 
starts with importing the raw impedance data provided by RTCA software as cell index (CI) 
followed by its normalization as suggested by Abassi and colleagues (Abassi et al., 2009) by 
dividing the cell indices for each time point after the compound was added by the cell index 
at the reference point. The last measurement taken before compound addition was 
considered as the reference point. For subsequent analysis, only the readings after 
compound addition were considered. Median polish procedure was implemented to detect 
and remove the outliers. To retain the complexity of the data while reducing the 
dimensionality of the data set, cubic smoothing splines were used to approximate the 
TCRPs. Spline basis coefficients were used as descriptors to construct the distance matrix 
which was used for hierarchical cluster analysis. A heat map was generated which displays 
the Z-transformed values of the 22 descriptors which equals to basis spline coefficients. 
Hierarchical cluster analysis of the reference compounds together with the test compounds 
was carried out. Clustering of test compounds with reference compounds with known activity 
was used to predict the mode of action of test compound. 
2.2.4 Automated microscopy – High content image analysis 
2.2.4.1 Equipment/Software 
Automated microscope consisting of the following 
 ImageXpress® Micro (IXM) 
 High-speed laser autofocus 
 Digital CCD-camera 
 300 Watt Xenon lamp 
 Filter sets:  DAPI 
    FITC 
    TRITC 
    Texas Red 
 Nikon Objective: 4X Plan Apo, NA (Numerical Aperture) 0.20 
    10X S Fluor, NA 0 50 
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    20X S Fluor, NA 0.75 
    40X Plan Apo, NA 0.95 
    60X Plan Fluor, NA 0.85 
    Biomek 
    MetaXpress® 2.0.013 
    AcuityXpress™ 2.1.0.2 
2.2.4.2 Preparation of HCA plates 
Six MTP’s (384 well) were prepared with KB-3-1 cells. Semi-confluent KB-3-1 cells were 
trypsinised and counted. 2500 cells/well were seeded (60 µL) leaving out all the edge wells 
due to technical difficulties of obtaining images using the automated microscope. Seeded 
plates were incubated at room temperature in a clean bench for one hour followed by 
incubation at 37°C for three hours. Meanwhile the 96-well stock plate containing the 
reference compounds, the HCA library, and the test compound dissolved in DMSO were 
placed at room temperature. The compounds included in the HCA library are similar to the 
one used in the xCELLigence system as shown in the previous section (Table 2.3). 
After incubation, the plates were treated with the reference and test compounds using a 
liquid handling robot with pintool device. Each pin of the pintool adds approximately 70-80 nL 
of the compound to each well with one dip. Plates were then incubated at 37°C for overnight. 
Following day the plates were fixed and permeabilised either with ice-cold methanol:acetone 
(1:1) or 3.7% formalin/Triton X-100 depending on the antibody set used for a plate. Then the 
plates were washed with 50 µL/well of PBS. In all the liquid discarding steps a microplate 
washer (Biotek) was used. Plates were blocked for an hour with 10% FBS made in PBS. 
Blocking solution was discarded followed by addition of 20 µL/well of primary antibody as 
shown in Table 2.4. Plates were centrifuged for one minute at 1000 rpm followed by 
incubation at 37°C for one hour or at 4°C for overnight with sides sealed with parafilm to 
avoid evaporation and covered in aluminium foil. All the phospho antibodies were by default 
incubated for overnight (O.N.) at 4°C as longer incubation provided with better image results. 
Plates were washed with PBS and incubated with the secondary antibody (20 µL/well) for 
one hour at room temperature. Then the plates were washed and incubated with 2 µg/mL of 
DAPI (20 µL) for ten minutes. Plates were washed once and stored with 50 µL/well of PBS 
for microscopic viewing. 
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Table 2.4: Antibody sets 
Set Target Source 
(reagent) 
Fixation Dilution Incubation 
time 
I Actin (Phalloidin) Formalin 1:400 1 h 
α-tubulin Mouse Formalin 1:6000 1 h 
II ER Rat MeOH/Acetone 1:4000 1 h 
Cytokeratin Mouse MeOH/Acetone 1:2000 1 h 
III Anillin Rabbit Formalin 1:1000 1 h 
SC-35 Mouse Formalin 1:4000 1 h 
IV Phospho-p38 Rabbit Formalin 1:400 O.N. 
Phospho-p44/42 Mouse Formalin 1:400 O.N. 
V c-Fos Rabbit Formalin 1:3000 1 h 
p53 Mouse Formalin 1:1600 1 h 
VI Phospho-CREB Rabbit Formalin 1:1000 O.N. 
Calmodulin Mouse Formalin 1:400 O.N. 
 
2.2.4.3 Acquisition 
Images were acquired using MetaXpress with the settings described below. 
Magnification: A 10X lens was used for both counting the cells as well as for high content 
image analysis (HCIA).  
Camera binning: The ratio between the signal (intensity of the object of interest, S) and the 
noise (background, N) determines how hard it will be for the software to distinguish important 
features in an image. If the ratio is small it is more difficult for the software to distinguish 
between the object of interest and background. One way to increase the S/N ratio is to bin 
pixels, i.e., to combine adjacent pixels to create an effect of a single larger pixel. This is of 
course at the cost of image resolution. A camera binning of 2, i.e., combining 2*2 pixels to 
form one big pixel was found to be adequate maintaining acceptable levels of S/N ratio and 
good image resolution. 
Camera gain: Specifies to the amplification to be applied to the camera output. Camera gain 
of 1 was found to give good image quality. 
Plate: Settings had to be changed for different plates based on plate dimensions like height, 
length, width, diameter and thickness of the well bottom. One particular plate setting was 
optimized for Corning plate (catalogue #: 3683) and the same was used for all HCIA. 
Well selection: Wells apart from the peripheral ones were selected to acquire images due to 
technical difficulties and also to get rid of edge effect encountered with KB-3-1 cells. The 
wells, in which neither the reference nor test compounds were added, were also excluded 
from image acquisition. 
Site selection: The more number of sites per well are chosen the more data will be acquired 
but this makes the process slow and takes up huge memory space. To count the number of 
cells more sites were considered but for HCIA four sites/well were optimal. 
Time lapse: Since HCIA is not a kinetic measurement, only one time point was considered. 
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Filters: Three filter sets were used: 
DAPI: excitation: 358 nm and emission: 461 nm – used to count the number of cells 
FITC: excitation: 494 nm and emission: 518 nm 
Texas Red: excitation: 577 nm and emission: 620 nm 
Autofocus option: There are two kind of autofocus option – laser and image based. Image 
based focusing selects the best focused image from multiple images which makes the 
operation slower whereas the laser based focusing sets the focus according to reflecting well 
bottom and then a manually set offset is utilized. This is faster but comes handy only if the 
object of interest is found in same distance from the well bottom. For HCIA always laser-
based focusing was taken into consideration over image-based. 
Wavelength settings: For each wavelength, exposure time and Z-position had to be 
adjusted manually. Initially the exposure time and Z-position was set based on negative 
control with DMSO only. 
2.2.4.4 Image analysis - software and application modules 
Acquired images were analysed using different application modules provided by 
MetaXpress. There are two different ways in which data can be analysed. 
Cell and image-based analysis: Cell-based analysis takes into consideration individual cell 
whereas image-based analysis takes an average of all the sites in a well. In HCIA both kind 
of analysis were used and provided with almost similar results. Each of these analyses can 
make use of different application modules based on the requirement. About 18 different 
application modules are provided by MetaXpress® out of which few are mentioned in Table 
2.5 which are quite useful for HCIA though mostly two were used, i.e., Multi Wavelength Cell 
Scoring (MWCS).and Transfluor. 
Table 2.5: Different modules in MetaXpress 
S. No. Application modules Purpose 
1 Angiogenesis tube formation Tube/vessel formation/inhibition in 
angiogenesis or development 
2 Mutli Wavelength Cell Scoring 
(MWCS) 
Cell Viability, Membrane potential, 
Cytotoxicity, Apoptosis 
3 Transfluor Studying intracellular structures 
4 Translocation Cell signalling by translocation 
5 Count nuclei Counting cells 
 
Multi Wavelength Cell Scoring (MWCS): This module can be used when more than one 
type of staining has been carried out. Parameters such as size of the object (minimum and 
maximum width) and stain intensities are taken into consideration for each wavelength. The 
settings were manually altered for each wavelength. In our study we used three different 
wavelength i.e. W1: DAPI, W2: FITC and W3: Texas Red. Descriptors provided by MWCS 
which are used later for analysis are mentioned in Table 2.6. 
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Table 2.6: MWCS descriptors 
Image-based analysis 
Total cells: Total number of cells based on DAPI. 
(%) Positive W2/W3: Number of cells stained for each wavelength (both absolute and 
relative) 
Scoring profile 1--/12-/1-3/123: absolute number of cells which are stained for different 
wavelength, For example: 1-3 shows the number of cells stained only for 1(W1) and 3 
(W3) but not 2 (W2) and so on. 
Cell-based analysis 
Total area: Nuclear surface 
Stained area W1/W2/W3: Coloured surface of respective staining 
Positive W2/W3: absolute number of cells stained for each wavelength 
Average/integrated intensity W1/W2/W3: average/integrated intensity of each stain 
 
Transfluor: This module was exclusively used for counting objects like pits and vesicles 
which were shown in case of SC-35 staining. Parameters such as the nucleus size, vesicle 
and pit count were taken into consideration. Descriptors provided by Transfluor are 
mentioned in Table 2.7. 
Table 2.7: Transfluor descriptors 
Image-based analysis 
Pit count per cell: Total number of pits per cell 
Pit average intensity: average intensity of all the pits in each well 
Vesicle count per cell: absolute number of vesicles per cell 
Vesicle average/integrated intensity: average or integrated intensity of all the vesicles in 
each well 
Nuclear count: Total number of cells based on W1 wavelength 
Nuclear average intensity: average intensity of all the cells in a well 
 
All the descriptors for cell based analysis were the same as for image-based analysis except 
that each cell is taken into consideration unlike image-based analysis. Also, all the cell 
based descriptors have a prefix cell, e.g., Cell:Total cell. 
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2.2.4.5 Data analysis – software and methodology 
Huge amount of data obtained from application modules are analysed using AcuityXpress™. 
Workflow adopted to analyse these data is mentioned below. 
Annotation: All the plates were first annotated before any analysis could be performed. 
Excel sheets containing names of all compounds and their concentration including negative 
control could be imported into AcuityXpress™ in csv format 
Normalization: The data was normalized against the negative control since for this HCIA we 
didn’t have positive control for all the test compounds. Each of the six plates was normalized 
separately based on cell or image based analysis. We used min-max scaling due to lack of 
positive control. All cell based parameters have a prefix of cell unlike image based 
parameter which has no prefix, e.g., Total cells, Average intensity etc. 
Creation of dataset: All the six plates used for one set of HCIA experiment were combined 
into one dataset. Two kinds of dataset can be created – cell-based and image-based. For 
each kind of dataset their respective descriptors should be used. 
Centre and scaling the data: Data were transformed by scaling, i.e., subtracting mean from 
each data point and centring i.e. dividing each data point by variance (average of squared 
difference from the mean). This gave Z-values and helped in good interpretation of the data. 
Different analysis method: After all the data transformation described above was carried 
out, data could be analysed using different analysis methods with AcuityXpress™ which 
provides both hierarchical and non-hierarchical clustering methods. 
Hierarchical clustering is good for finding the relationship of each row or column in the 
dataset to every other row or column and also when one does not have prior knowledge of 
how the data will be clustered, as hierarchical clustering does not set the number of clusters 
to form before the analysis. In case of HCIA, hierarchical analysis was found to be more 
useful as we wanted to know how each compound clusters with every other compound 
included in the dataset. Hierarchical clustering produces tree structure called dendrogram 
which presents the distance of similarity between the clustered rows or columns. Figure 2.1 
shows a typical row hierarchical cluster. 
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Figure 2.1: Typical example of hierarchical cluster analysis through heat map 
Graphical representation of data where the Z-values for each measured parameter is 
represented by colours. In Figure 2.1 each coloured column indicates a descriptor and the 
colour gradations are based upon the Z-score. Z score is standard deviation from mean. For 
example a Z score of 0 has the same value as the mean whereas a Z score of 1 is exactly 
one standard deviation above the mean. Similarly a Z score of -1 is one standard deviation 
below the mean. Compounds with similar mode of action cluster together.  
Non-hierarchical clustering method is used when one is more interested in separating rows 
(cells, compounds) into distinct classes than in the relationships between the classes. It 
forces the data into user-defined number of clusters. In this case the user has prior 
knowledge about the number of clusters they want to form. In our case, we performed gap 
statistics to identify the number of main clusters in the whole dataset and then used non-
hierarchical clustering method to find that many clusters. This kind of clustering method 
includes Principal Component Analysis (PCA) and Self-Organizing Map (SOM). 
SOM is used to group the rows together with similar pattern over the columns. The clusters 
are arranged in a two-dimensional grid. The benefit provided by this is a simple 
representation of similarity between the clusters. Clusters showing similar profile across 
rows occupy nearby slots on the grid whereas dissimilar ones will occupy distant slots. PCA 
on the other hand is used to produce a low dimensional summary of the data. When a large 
dataset like HCIA is being analysed, it’s worthwhile to analyse the correlations among the 
parameters to ensure that measurements that should be correlated, are actually correlated. 
This can be done using PCA. 
2.2.5 Immunofluorescence 
Cell seeding: For immunofluorescence staining, cells were cultured on sterile coverslips 
with a diameter of 13 mm placed into the wells of a four well plate. PtK2 or A-549 cells were 
harvested by trypsinising a semi-confluent culture and diluted with their respective medium 
at 1:3 ratio. 750 μL of the diluted cell suspension was added to each well and incubated 
overnight to ensure complete adherence. Compounds were added the following day. Care 
was taken that the concentration of the vehicle solvent MeOH/DMSO did not exceed 
0.5%/0.1% respectively. The cells were incubated with the compounds at 37°C for overnight. 
Descriptors Dendrogram 
Correlation scale 
Z score 
Compound and its target 
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Fixation: After compound incubation, the cells were either fixed with 750 µL of 3.7% 
formalin or methanol:acetone (MeOH:Ac; 1:1) for 10 minutes. The cells were washed once 
with sterile PBS and then treated for 5 min with 0.1% Triton X-100 in case of formalin fixation 
After Triton X-100 treatment, the cells were again washed once with sterile PBS. 
Staining: Appropriate antibodies were used for staining. The primary antibody dilution varied 
with the antibody in use. Usually it was in the range of 1:100 to 1:500. The dilutions were 
prepared in sterile PBS containing 10% FBS. The cells were incubated for one hour with 240 
µL of the primary antibody in each well at 37°C and then washed with PBS twice. Then the 
cells were incubated with 240 µL of a secondary antibody tagged by a fluorochrome for one 
hour (Alexa Fluor 488 or 594). The secondary antibody was diluted to 1:500 with sterile PBS 
containing 10 % FBS. The cells were washed twice with PBS. The coverslips were then 
removed from the wells, excess liquid removed by soft tissue paper and embedded (with the 
cells facing down) onto a microscope slide with a drop of embedding medium which either 
excluded or included DAPI depending on the requirement to stain the nucleus (ProLong 
Antifade). 
Documentation: Images were taken with the CCD camera Axiocam mounted on the 
fluorescence microscope Axioplan (both from Zeiss). Neofluor objectives with magnifications 
of 63X and 100X were used for viewing. All the images were taken at 63X magnification. 
2.2.6 SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) was performed 
using commercially available gels from Bio Rad (4-20% Tris HCl gradient gel). Semi-
confluent KB-3-1 cells were lysed using MPER® cell lysis buffer from Thermo Fisher 
Scientific and supplemented with HALT® protease/phosphatase inhibitor from Roche (1X). 
Protein was quantified using the Bradford method in BCA protein assay kit from Thermo 
Fisher Scientific. 
20 µg of protein from the lysate was mixed with 5 µL of 4X SDS loading dye (Roth) and 
heated at 96°C for 12 minutes. Samples were left at room temperature for one min and short 
centrifuged to bring down any liquid which had evaporated to the Eppendorf’s cap. The 
sample was then loaded to the individual wells of the SDS gel placed in a vertical 
electrophoresis tank with 1X SDS running buffer. A protein marker (10-250kDa range) was 
also loaded to one well. Electrophoresis was carried out at 120 V for 1.5 hours or till the 
loading front reached the end of the gel. Now this gel can either be stained with Coomassie 
Brilliant Blue or subjected to Western blot. 
2.2.7 Western blot 
Transfer: The protein bands from the SDS PAGE gel were transferred onto nitrocellulose 
membranes by a semi dry transfer method. The nitrocellulose membrane and extra thick 
Whatman filter paper was cut into 6 x 9 cm dimension. The membrane, 2 extra thick 
Whatman filter papers and the gel with protein bands were then soaked in 1X blotting buffer 
with 20% methanol for 30 minutes with gentle stirring to equilibrate the gel and remove SDS. 
Then the membrane was placed onto extra thick Whatman filter paper. The gel was layered 
over the membrane and another extra thick Whatman paper was placed. A roller was gently 
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rolled over this stack of paper and gel to remove any possible air bubbles lodged which 
might interfere with efficient transfer of protein bands. The transfer was allowed to proceed 
at constant voltage of 15V and 500 mA for 30 minutes.  
Blocking and antibody incubation: The nitrocellulose membrane was then removed from 
the transfer cassette and washed in TSBT buffer for 5 minutes before blocking it with 5 % 
BSA prepared in TBST buffer at room temperature for two hours or at 4°C for overnight to 
block unspecific binding sites. The membrane was then shortly washed once with TBST. 10 
µL of the stock antibody was added to 10 mL of TBST solution containing 1% BSA. This 
antibody mix was added to the blot and incubated at room temperature for 2 hours or at 4°C 
overnight. The primary antibody solution was removed, and blotted membrane washed 5 
times (for 5 min each) with TBST. The blot was then incubated with 10 mL TBST containing 
1% BSA and 5 µL of the secondary antibody conjugated to HRP. After incubation the 
membrane was washed thrice for 5 min each with TBST and prepared for detection. 
Detection: Supersignal West Pico® or Supersignal West Femto® chemiluminescence 
detection kit (Thermo Fisher Scientific) was used for detection. The membrane was 
incubated with a mix of Enhancer and Stable Peroxide Buffer in equal parts for 5 minutes. 
The membrane was then transferred to an X-ray cassette. In the dark room an X-ray film 
was placed in the cassette and exposed for 0.5 to 5 minutes. The film was developed using 
an Optimax developing machine. 
2.2.8 Coomassie Blue staining 
Coomassie staining was carried out using Coomassie Brilliant Blue G-250 powder from 
Thermo Fisher Scientific. 1 g of powder was dissolved in 400 mL methanol and 100 mL 
acetic acid. The volume was made up to 1000 mL with distilled water. The SDS gel was 
removed from the electrophoresis cassette and washed once for 5 min in filtered Millipore 
water to remove the salts of the running buffer. Then the gel was immersed in Coomassie 
Blue solution and incubated at room temperature for a minimum of 1 h or overnight with 
gentle stirring. After staining the gel, the Coomassie Blue stain was removed and the gel 
destained with a solution made up with 30% methanol and 10% acetic acid. Balls made with 
Kim wipes were placed at the corner of the plate to speed up destaining as it removes any 
precipitate left by the staining solution. The gel was left in the destaining solution for a 
minimum of 2 h or till the bands were visible. Once the bands were clearly visible, destaining 
solution was replaced by distilled water. 
2.2.9 DARTS 
Preparation of cell lysate: KB-3-1 cells were cultured to 70-80% confluency in a 75 cm2 
(T75) cell culture flask. The cells were scraped and centrifuged at 3000 rpm for 5 min. The 
cell pellet was washed once with PBS and centrifuged again to remove any left out media. 
The pellet was resuspended in 800-1000 µL of MPER® lysis buffer (Pierce) based on the 
size of the pellet in a 1.5-mL Eppendorf tube and subjected to cell lysis on ice for 15-20 min. 
After cell lysis, the tubes were centrifuged at 4°C for ten minutes at maximum speed. The 
supernatant was collected and the protein content was measured using Bradford’s assay. 
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Digestion with pronase®: 100 µg of the protein lysate was incubated with the compound at 
varying concentration and methanol (negative control) for two hours on ice. The mixture was 
digested with 0.03 µg of Pronase® (Roche) at 37°C for 30 min. The digestion was stopped by 
heating with 5 µL 4X loading dye (Roth). 
Detection: The sample was separated by SDS-PAGE (4-20% Tris-HCl gels) and either 
subjected to Coomassie Blue staining or transferred onto a nitrocellulose membrane. The 
membrane was then subjected to western blotting with the required antibodies and made 
visible by chemiluminescence. 
2.2.10 siRNA knockdown 
Transfection: Confluent cells (KB-3-1 or L-929) were trypsinised and counted using cell 
counter. In a 6-well plate 2*105 cells/well (2 mL) were seeded and incubated at 37°C until 
they were 60-80% confluent which usually is 18-24 h. After 24 h, cells were provided with 2 
mL of fresh complete media and incubated at 37°C for one hour prior to transfection. During 
this one hour, a transfection mix was prepared from solution A and B for each well. Solution 
A consisted of 100 nM of siRNA in 150 µL of media without FBS. Solution B consisted of 9 
µL of Lipofectamine® RNAiMAX reagent and 150 µL media without FBS. FBS or any kind of 
serum is excluded from the transfection mix preparation as it interferes with good 
transfection efficiency. Solution A was gently mixed with B and allowed to incubate at room 
temperature for 10 min. At the end of one hour incubation of cells with fresh complete media, 
the 6-well plate was removed from the incubator and 1.8 mL of the medium in each well was 
aspirated out. 300 µL of the transfection mix was added to each well and incubated at 37°C 
for one hour to allow an efficient uptake of siRNA by the cells. Later 1.5 mL of complete 
growth media was added to each well and the plates incubated at 37°C. After 48 h the 
media was discarded and replaced with fresh complete media. Test compounds and vehicle 
control were added to these transfected cells and incubated at 37°C for overnight. 
Preparation of cell lysate: After incubation with test compound and vehicle control the 
media was discarded. The plate was placed on ice, 200 µL of MPER® lysis buffer added to 
each well and incubated for 10 min with gentle shaking to lyse the transfected cells. The well 
contents were placed in an Eppendorf tube and centrifuged at 4°C for ten minutes at 
maximum speed. Supernatant was collected and protein estimation was carried out using 
Bradford’s assay. 
Detection: The sample was separated by SDS-PAGE (4-20% Tris-HCl gels) and the protein 
bands transferred onto a nitrocellulose membrane. The membrane was then subjected to 
Western blotting with the required antibodies and made visible by chemiluminescence. 
2.2.11 Apoptosis assay with cell death detection ELISA PLUS  
The levels of apoptosis in the knockdown cells were measured using the cell death detection 
ELISA PLUS kit provided by Roche. The assay is based on a quantitative sandwich-enzyme-
immunoassay principle using mouse monoclonal antibodies directed against DNA and 
histones. It’s a photometric determination of mono- and oligonucleosomes in cell lysates 
produced in case of induced cell death. 20 µL of knockdown cell lysate was placed in a 
streptavidin-coated microplate (MP) and 80 µL of the Immunoreagent was added. 
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Immunoreagent was prepared by mixing 1/20 volume Anti-DNA-POD and 1/20 volume Anti-
histone-biotin with 18/20 volume incubation buffer. Anti-DNA-POD and Anti-histone-biotin 
are monoclonal antibodies from mouse and bind to DNA and histone component of 
nucleosomes respectively. Anti-DNA-POD also gives a colour reaction whereas anti-histone-
biotin captures the immunocomplex via biotin to the coated MP. MP with the lysate and the 
immunoreagent was incubated at room temperature for two hours with gentle shaking (300 
rpm) after covering with adhesive foil. Solution was thoroughly removed by suction and 
rinsed thrice with 300 µL of ready to use incubation buffer provided in the kit. After solution 
was carefully removed, 100 µL of ABTS solution (provided in kit) was pipetted to each well 
and the plates incubated on a plate shaker at 250 rpm until colour developed. Colour 
development was stopped by adding 100 µL of ABTS stop solution and colour intensity was 
measured at 405 nm with reference wavelength of 490 nm using a plate reader. 
2.2.12 Caspase-Glo® 3/7 assay 
Caspase-Glo® 3/7 assay is a luminescent assay which measures the activities of caspase-3 
and -7 which plays an effector role in apoptosis. Addition of Caspase-Glo® 3/7 reagent leads 
to cell lysis and caspase cleavage of the luminogenic substrate which contains the 
tetrapeptide sequence DEVD (Asp-Glu-Val-Asp) and a glow-type luminescent signal by 
luciferase. Luminescence is proportional to the amount of caspase activity. Caspase-Glo® 
3/7 reagent was prepared before starting the experiment by combining the substrate with the 
buffer provided in the kit. 100 µL of the lysate was taken in a white bottom 96-well plate. 
Equal volume of the caspase-Glo® 3/7 reagent was added and incubated at room 
temperature for two hours. Luminescence was measured using a plate reader.
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3 Results 
3.1 Bioprofiling using advanced HCA methods 
In order to judge the biological behaviour of a compound, its mode of action becomes 
paramount. As there is no easy and clear cut way how to proceed in that aspect, one task of 
this study was to evaluate modern approaches of high content analysis in getting hints about 
the mode of action of a compound. Treatment of cells with biologically active compounds 
brings about a change in their cellular status, inner structure and general morphology which 
can either be analysed by impedance monitoring of cell cultures or by comparing images of 
the cells showing phenotypic changes. The general idea is to compare new compounds of 
unknown mode of action with reference compounds whose mode of action is already known. 
For the reference library 63 compounds were selected which are commercially available. 
The compounds were dissolved in DMSO in their optimum concentration as given in Table 
2.3. 
3.1.1 Image analysis 
The first profiling method investigated was high content image analysis (HCIA) using 
automated microscopy. In this approach KB-3-1 cells were treated overnight with the set of 
reference compounds and stained with 12 different antibodies which bind to a broad range of 
proteins, and are then made visible by fluorescence. Fluorescence images of cells were 
acquired then by automated microscopy. Data obtained from these images are transformed 
and used to define descriptors (Table 2.6 & Table 2.7) which form profiles for the 
compounds of interest that can then be compared using different statistical methods like 
hierarchical clustering, SOM and PCA. 
Cluster analysis of profiles (Figure 3.1) of all the reference compounds based on the effect of 
the compounds on KB-3-1 cells provided us with different clusters. Few of the clusters are 
highlighted to show the reliability of the method, its strengths and weakness. Box 1 shows a 
clustering of two compounds which affect protein synthesis at a Euclidean distance of 0.57. 
Both cycloheximide (McKeehan and Hardesty, 1969) and myriaporone (Muthukumar et al., 
2013) have been found to affect translational machinery at different levels. Box 2 shows a 
clustering of 6 compounds, out of which 4 affect microtubular dynamics at various Euclidean 
distances ranging from 0.54 to 0.72. But argyrin A and cruentaren A were found in the same 
group though they do not affect microtubule. This has been observed rather often, also in 
case of impedance measurement. This is probably due to some off-target which needs 
further investigation. Box 3 shows a clustering of the histone deacetylase (HDAC) affecting 
compounds, trichostatin (Furumai et al., 2001) and oxamflatin (Kim et al., 1999) at Euclidean 
distance of 0.56. PMA (phorbol-12-myristate-13-acetate) was also found in that group 
probably also due to some off-target. Box 4 shows a clustering of the V-ATPase inhibitors 
apicularen and archazolid B (Huss et al., 2005) at a Euclidean distance of 0.8. Box 5 shows 
a clustering of kinase inhibitors (0.7 to 0.85) together with the actin interfering compound 
chivosazol A. The next box (6) highlights a rather heterogeneous group that will be 
discussed later. Box 7 shows a clustering of compounds all of which affect the protein 
synthesis at different levels. Finally box 8 clusters together compounds affecting actin at a 
Euclidean distance of 0.42.  
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Figure 3.1: Hierarchical cluster analysis of 13-descriptor profiles of reference compounds 
generated by automated microscopy and image analysis 
KB-3-1 cells were treated with reference compounds overnight. Descriptors considered: Total number 
of cells, total number of positive cells for FITC and Texas Red, % positive W2 and W3, pit count per 
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cell, pit average intensity, pit total area, vesicle count per cell, vesicle average intensity, vesicle area 
per cell, nuclear area per cell and nuclear average intensity. 
SOM analysis performed on reference compound profiles is shown in Figure 3.2. This grid 
depicts 3*3 clusters which contain the coloured profiles of all the compounds in the cluster. 
The graph within each cluster shows the average trace of all the descriptors. The title bar 
shown above each cluster indicates the number of compounds included. Gray shade of the 
title bar represents the relative number of compounds in each cluster. A white bar indicates 
cluster with highest number of compounds, and black one the cluster with the least number. 
SOM analysis also arranges the clusters according to their similarity to each other. Similar 
clusters are placed close together while dissimilar ones are separated. Clusters diagonally 
opposite on the grid are essentially anti-correlated. The cluster with the pink border shows 
microtubule affecting compound along with others. This cluster includes 12 compounds. 
Clusters at the extremes tend to have the most variance, while clusters in the centre have 
least variance. Grouping shown by hierarchical clustering and SOM do not necessarily have 
to be similar. 
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Figure 3.2: Self-organising maps (SOM) of descriptor profiles of reference compounds 
generated from image data gained by automated microscopy 
KB-3-1 cells were incubated with the compounds overnight. The chosen descriptors were the same 
as used for hierarchical clustering (Figure 3.1). 
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PCA places all the compounds according to their descriptors profiles in a 3 dimensional 
space without premature categorization of the data. Figure 3.3 shows spread of all the 63 
compounds in the form of dots. A few of these dots have been marked red; these dots 
represent those compounds which had clustered together in the cluster of SOM, which was 
highlighted in pink in Figure 3.2. 
       
Figure 3.3: Principal Component Analysis (PCA) of the reference compounds according to 
descriptor profiles that were generated from image data by automated microscopy. 
KB-3-1 cells were incubated with the compounds overnight. The descriptors chosen were the same 
as in hierarchical cluster analysis and SOM. The highlighted (red) dots show the compounds that 
were grouped in the upper left cluster by SOM analysis (Figure 3.2). 
 
3.1.2 Impedance profiling 
The second method of High Content Analysis that was investigated is based on impedance 
monitoring of cell cultures incubated with the compounds of interest. Impedance was 
monitored in a culture of L-929 cells which were seeded in wells of an E-plate which has got 
gold electrodes integrated in its well bottoms. Treatment of the cells with the compound 
brings about a change in their morphology and these changes are reflected in the change in 
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impedance and were measured over a period of 4 days. A dimensionless parameter, the 
Cell Index (CI) was derived as a relative change in measured electrical impedance to 
represent the cell status. The CI value increases as the cells start to adhere and alters with 
change in cell status such as cell morphology, adhesion or viability. Every compound gives a 
characteristic impedance curve which is depending on its mode of action. When compared 
with that of the reference compounds for which the MoA is already known, it should provide 
possible hints of the pathway targeted.  
After incubation, the raw data were analysed using an R script for normalisation and Z-score 
calculation. The Z scores were the basis for the creation of compound profiles, depicted as 
heat maps, which were used for hierarchical cluster analysis with reference compounds as 
shown in Figure 3.4. For this analysis Euclidean distance was used to establish a similarity 
matrix.  
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Figure 3.4: Hierarchical cluster analysis of reference compounds using an xCELLigence 
system 
L-929 mouse fibroblasts were incubated with the compounds for 4 d. The resulting changes in 
impedance were used to form a profile for each compound. The basis are coefficients of spline 
approximation curves. Each of the 22 coloured columns represents a short time period. The gradation 
in the colour code signifies their Z-score i.e. distance from mean divided by the standard deviation. 
The results of a hierarchical cluster analysis show compounds with similar modes of action in close 
proximity.  
The cluster analysis (Figure 3.4) showed grouping of compounds based on their impedance 
profile. Box 1 show a clustering of compounds inhibiting transcription, e.g., both 
camptothecin (Desai et al., 2001) and etoposide (van Maanen et al., 1988) are 
topoisomerase I inhibitor whereas saframycin Mx1 also inhibits transcription but via a 
different mechanism (Irschik et al., 1988). Cytochalasin D also clusters with this group at 
varying range of Euclidean distances (2.48 to 3.39) though it acts on actin by inhibiting its 
polymerisation (MacLean-Fletcher and Pollard, 1980). Box 2 shows a clustering of actin 
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polymerisation inhibiting compounds at a Euclidean distance of 2.8. Box 3 shows a 
clustering of Taxol® and epothilone, both being microtubule stabilizers (Bollag et al., 1995; 
Horwitz, 1994). Scriptaid (Su et al., 2000) and Oxamflatin (Kim et al., 1999), inhibiting HDAC 
clustered together as shown in box 4. Compounds inhibiting translation at various levels are 
clustered in box 5. Box 6 shows a clustering of kinase inhibitors at a Euclidean distance of 
0.4. 
3.2 Cytotoxicity profiling of selected compounds with 
mammalian cell lines  
Once both the profiling methods were established they should be applied to elucidate the 
mode of action of selected compounds, i.e., jerantinine E, two paleo-soraphens, and two 
disorazols. 
Different mammalian cell lines were used to test the toxicity of the selected compounds. 
These were human cancer cell lines including KB-3-1, PC-3, A-549, A-431 and MCF-7, 
transformed cell lines from mouse and potoroo – L-929 and PtK2, and primary HUVECs. 
Cells were incubated in 96-well micro-titre plates with serially diluted compounds for a period 
of 5 days. The influence of the compounds on the viability of the cells was measured by an 
MTT assay. Table 3.1 shows that Dsz A1 and Z inhibited the cell viability in nanomolar 
ranges irrespective of cancer or primary cell line whereas the others were much less active. 
Table 3.1: Cytotoxicity of alkaloids and polyketides in mammalian cells 
The values represent the IC50 of the each compound measured by an MTT assay 
Cell lines Jerantinine 
E (µM) 
Genetic 
soraphen A 
(µM) 
Genetic 
soraphen B 
(µM) 
Dsz A1 (nM) Dsz Z (nM) 
L-929 3.9 >76 >76 0.05 1.14 
KB-3-1 1.9 >76 30.2 0.0016 0.24 
A-431 n.d n.d n.d 0.26 0.04 
A-549 n.d n.d n.d 1.2 0.4 
PC-3 n.d n.d n.d 0.1 0.23 
PtK2 3.6 n.d n.d 0.4 0.8 
MCF-7 n.d n.d n.d 0.4 0.17 
HUVEC n.d n.d n.d 0.05 0.0005 
 
Jerantinine E was also tested by others against breast and lung cancer cell lines (Frei et al., 
2013). The moderately invasive breast cancer cell line MCF-7 and the highly invasive cell 
line MDA-MB-231 were incubated with jerantinine E and showed IC50 values between 4.4 
µM and 6.0 µM after 24 and 72 h, respectively. Similar assays were carried out with lung 
cancer cell line A-549 and adenosquamous carcinoma cell line HT-178 which showed IC50 
values between 1.0 µM to 8.8 µM after 24 and 72 h.  
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3.3 The mode of action of jerantinine E 
For time dependent cell response impedance profiling L-929 cells were treated with 
jerantinine E at a concentration of 14 µM. After compound addition, cell response was 
measured for the next four days. 
3.3.1 Impedance profiling with jerantinine E 
After compound incubation, the raw data were analysed using an R script for normalisation 
and Z-score calculation. The Z scores were the basis for the creation of compound profiles, 
depicted as heat maps, which were used for hierarchical cluster analysis with reference 
compounds as shown in Figure 3.5. For this analysis the Euclidean distance was used to 
form a similarity matrix. The cluster analysis showed jerantinine E in closest neighbourhood 
to the microtubule affecting compounds colchicine with a Euclidean distance of 0.45. 
 
Figure 3.5: Hierarchical cluster analysis for jerantinine E using xCELLigence system 
L-929 mouse fibroblasts were incubated with jerantinine E for 4 d. The resulting changes in 
impedance were compared with those of reference compounds. Basis coefficients of spline 
approximation curves are used for hierarchical cluster analysis. The results show compounds with 
similar modes of action in close proximity. Each of the 22 coloured columns represents a short time 
period. The gradation in the colour code signifies their Z-score i.e. distance from mean divided by the 
standard deviation. Red boxed area shows the clustering of jerantinine E with colchicine, a known 
microtubule destabilizer. 
3.3.2 Effect of jerantinine E on the microtubular network in the cell 
Based on impedance profiling jerantinine E was found to cluster with microtubule affecting 
compound like colchicine and disorazol, a possible effect on cellular microtubules and 
tubulin polymerisation in vitro was investigated. 
PtK2 cells were incubated with jerantinine E at varying concentrations. Methanol treated 
cells were taken as negative control. After overnight incubation at 37°C, cells were fixed and 
stained with an anti α-tubulin antibody followed by an Alexa Fluor 488 tagged secondary 
antibody. DAPI was used to stain the nucleus. An effect on the nucleus was evident at a 
concentration of 5.5 µM (Figure 3.6 B), microtubular network started to disrupt from 16 µM 
(Figure 3.6 C) and was almost completely destroyed at 26 µM (Figure 3.6 D). 
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Figure 3.6: Effect of jerantinine E on cellular microtubules 
Immunofluroscence staining of PtK2 cells which have been incubated with methanol (A) and 
jerantinine E at varying concentrations for overnight. Multinucleated cells are formed at 2 µg/mL (5.5 
µM, B). At 6 µg/mL (16 µM, C) microtubules started to disintegrate and were almost completely 
disrupted at 10 µg/mL (26 µM, D). α-tubulin was probed using anti-α-tubulin antibody (green) and the 
nucleus (blue) was stained by DAPI. 
3.4 The mode of action of paleo-soraphens 
3.4.1 Impedance profiling with paleo-soraphen A and B 
To characterize the action of the two paleo-soraphens, impedance profiling was carried out 
with L-929 cells at a concentration of 16 µM. 
The data obtained from the resulting curves were used for hierarchical analysis together with 
the standard set of reference compounds. As can be seen from Figure 3.7, paleo-soraphen 
A (A) clusters with soraphen A at a Euclidean distance of 0.91, which makes it likely that it 
has the same mode of action. But paleo-soraphen B (B) did not cluster with its parent 
compound and found in close neighbourhood with camptothecin, a topoisomerase I inhibitor 
(Euclidean distance = 1.2). 
(A) 
(C) 
(B) 
(D) 
RESULTS 
 
55 
 
 
Figure 3.7: Hierarchical clustering for paleo-soraphen using xCELLigence system 
L-929 mouse fibroblasts were incubated with paleo-soraphen A & B for 4 d. The resulting change in 
impedance was compared with those of reference compounds. Basis coefficients of spline 
approximation curves are used for hierarchical cluster analysis. The results show compounds with 
similar modes of action in close proximity. Each of the 22 coloured columns represents a short time 
period. The gradation in the colour code signifies their Z-score i.e. distance from mean divided by 
standard deviation. The red boxed areas show a clustering of paleo-soraphen A (A) with soraphen A 
whereas paleo-soraphen B (B) clusters with camptothecin. 
3.4.2 Effect of paleo-soraphen on speckle size 
Impedance profiling provided the indication that both paleo-soraphens have different targets. 
Paleo-soraphen A clustered with soraphen A but paleo-soraphen B showed a totally different 
and unexpected cluster behaviour. To investigate whether it has an effect similar to 
camptothecin, an immunofluorescence staining was carried out with PtK2 cells. Large 
volume of nuclear space is occupied by so called speckles were mRNA is transcribed and 
processed further for protein synthesis. These speckles can be detected using an anti-
splicing factor SC-35 antibody. In mammalian cell nucleus, the splicing factors are 
concentrated in about 20-50 speckles, depending on the transcriptional activity. 
Topoisomerase I is a protein kinase directed towards the mRNA splicing factor SC-35. When 
treated with camptothecin (Figure 3.8 D), a known topoisomerase I inhibitor, the speckle 
structure within the nucleus changed from intermingled loops and dots to much smaller 
speckles with loss of loops (Elias et al., 2003). The same morphological changes were seen 
in cells treated with paleo-soraphen B (Figure 3.8 C). In contrast to that, paleo-soraphen A 
(Figure 3.8 A), which clustered with soraphen A in impedance profiling, showed speckle 
morphology similar to soraphen A treated cells (Figure 3.8 B).  
A 
Soraphen 
B 
Camptothecin 
DMSO 
SaframycinMx1 
Etoposide 
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Figure 3.8: Paleo-soraphen affects the SC-35 speckle size 
PtK2 cells were incubated with paleo-soraphen A (A, 30 µg/mL) and soraphen A (B, 30 ng/mL) for 
overnight and probed for the effect on speckle size by using anti SC-35 antibody (red) in the nucleus. 
Speckles in A and B are in form of intermingled loops whereas the speckles are much smaller and 
evenly distributed in case of PtK2 cells treated with paleo-soraphen B (C, 30 µg/mL) and resembles 
that of camptothecin (D) which was taken as the positive control. 
The speckle sizes were quantified and are shown in Figure 3.9. The graph shows clear 
difference between cells treated with paleo-soraphen B and camptothecin on one side and 
paleo-soraphen A and soraphen A on the other side. 
(A) (B) 
(C) (D) 
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Figure 3.9: Effect on SC-35 speckle size by genetic paleo-soraphens 
PtK2 cells were immunostained for SC-35 speckles using anti-SC-35 antibody after treating them with 
paleo-soraphens. The speckle size is reduced when incubated with camptothecin and paleo-soraphen 
B. 
3.5 Profiling of disorazols 
3.5.1 Impedance profiling 
3.5.1.1 Disorazol A1 
For impedance readout usually the IC90 for L-929 cells are applied but in case of Dsz A1 the 
reduction in cell viability did not reach the stage of IC90 even with highest concentration 
showing that probably Dsz A1 is not cytotoxic but cytostatic in nature. However a 
concentration of 0.6 nM was used. Also a lower concentration of 1.3 pM was used to see 
any difference in the output but in this case it always clustered with vehicle control. 
L-929 cells were treated with Dsz A1 for a period of 4 days and the results obtained from 
impedance monitoring were used to create a distance map that was used for hierarchical 
cluster analysis with reference compounds as shown in Figure 3.10. For this analysis 
Euclidean distance was used as similarity matrix. The closest neighbour of Dsz A1 was the 
microtubule affecting compound Taxol® at a Euclidean distance of 0.52. Other microtubule 
affecting compounds like tubulysin B, griseofulvin, nocodazole and epothilone B had 
distance of 0.58, 0.66, 0.69 and 0.73, respectively. 
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Figure 3.10: Hierarchical cluster analysis of impedance profiling data for Dsz A1 
L-929 mouse fibroblasts were incubated with Dsz A1 for 4 d. The resulting changes in impedance 
were compared with those of reference compounds. Basis coefficients of spline approximation curves 
are used for hierarchical cluster analysis. The results show compounds with similar modes of action in 
close proximity. Each of the 22 coloured columns represents a short time period. The gradation in the 
colour code signifies their Z-scores i.e. distance from mean divided by standard deviation. The 
snapshot shows the clustering of Dsz A1 with microtubule affecting compounds. 
3.5.1.2 Disorazol Z 
L-929 cells treated with Dsz Z did not reach IC90 as it is also cytostatic in nature like Dsz A1. 
A concentration of 7.4 nM was used to treat and incubate the cells for a period of 4 days for 
impedance profiling. 
As described in the previous section, characteristic impedance curves were obtained and 
analysed. Figure 3.11 show a clustering of Dsz Z with the microtubule affecting compound-
colchicine with a Euclidean distance of 0.92. It has lower distance (0.78) with jerantinine E 
(Jer E). 
 
Figure 3.11: Hierarchical cluster analysis of Dsz Z using xCELLigence system 
L-929 mouse fibroblasts were incubated with Dsz Z for 4 d. The resulting changes in impedance were 
compared with those of reference compounds. Basis coefficients of spline approximation curves are 
used for hierarchical cluster analysis. The results show compounds with similar modes of action in 
close proximity. Each of the 22 coloured columns represent a short time period, the gradation in the 
colour code signifies their Z-score i.e. distance from the mean divided by standard deviation. The 
snapshot shows the clustering of Dsz Z with colchicine and jerantinine E. 
3.5.2 Image profiling 
3.5.2.1 Disorazol A1 & Z 
Image data were obtained from KB-3-1 cells treated overnight with Dsz A1 and Z. Incubated 
cells were stained later with 6 pairs of antibodies as described earlier and prepared for 
automated microscopy. The images acquired were analysed in the same manner as the 
reference compounds. 
Hierarchical clustering analysis of Dsz A1 and Z with reference compounds is shown in 
Figure 3.12, Dsz A1 clustered with the MAP kinase affecting compound SB202190 and 
Dsz A1 
Taxol 
Tubulysin B 
Griseofulvin 
Nocodazole 
Epothilone B 
Scriptaid 
Oxamflatin 
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rapamycin at a Euclidean distance of 0.917 and 0.883, respectively. This differed from 
cluster analysis obtained with impedance data. Dsz Z clustered at a Euclidean distance of 
0.961 with argyrin A and with the kinase inhibitor – indirubin monoxime at 0.889  
 
Figure 3.12: Hierarchical cluster analysis of descriptor profiles of Dsz A1 and Z and reference 
compounds using automated microscopy 
Images of KB-3-1 cells treated with Dsz A1 and Dsz Z along with reference compounds were prepared 
as per the HCIA protocol. The images were captured using an automated microscope., Descriptors 
considered: Total number of cells, total number of positive cells for FITC and Texas Red, pit count per 
cell, pit average intensity, vesicle count per cell, vesicle average intensity, nuclear count, nuclear area 
per cell and nuclear average intensity. 
 
 
 
Hpd 
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3*3 clusters were formed out of which only two clusters in which Dsz A1 and Z appeared are 
shown in Figure 3.13. Dsz A1 grouped with not just compounds like kinase inhibitors 
PD169316 and rapamycin but also with other compounds, e.g., etoposide which is a 
topoisomerase inhibitor. The similar was the case with Dsz Z which grouped with 
compounds affecting different targets like chivosazol affecting actin and griseofulvin that 
affects microtubules. 
 
 
Figure 3.13: Self-Organizing Map (SOM) analysis of profiles of Dsz A1 and Z and reference 
compounds by automated microscopy 
KB-3-1 cells were incubated overnight. SOM analysis was applied on profiles gained from the raw 
data of images acquired by automated microscopy. Only the relevant clusters of a 3*3 grouping are 
shown. Descriptors considered: Total number of cells, total number of positive cells for FITC and 
Texas Red, pit count per cell, pit average intensity, vesicle count per cell, vesicle average intensity, 
nuclear count, nuclear area per cell and nuclear average intensity. 
PCA was carried out and depicted in Figure 3.14. It shows proximity of Dsz A1 and Z with 
rapamycin and indirubin monoxime, respectively, included in the reference library. Both are 
well established and known to affect the kinases. 
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Figure 3.14: Principal Component Analysis (PCA) of Dsz A1 and Z. Profiles were generated 
from images acquired by an automated microscope 
KB-3-1 cells were incubated overnight. PCA analysis was applied on the transformed data obtained 
from automated microscope. 3 dimensional space shows the spread of all the compounds based on 
the level of similarity. Highlighted dots show closeness of Dsz A1 and Z to kinase inhibitors. 
 
3.6 Identification of the mode of action of disorazol A1 
Based on the hints provided by the high content analysis approaches, impedance monitoring 
with the xCELLigence and the image profiling using automated microscope, Dsz A1 was 
further tested in various assays to ascertain its biological mechanism of action. 
3.6.1 Nuclear localization of p53 
To test the effect on the localisation of tumour suppressor protein p53 as seen earlier by 
(Elnakady et al., 2004). A-549 lung cancer cells were incubated with Dsz A1 at 17.1 pM for 
12-14 h at 37°C. Later the cells were fixed and permeabilised with formalin/Triton X-100 and 
immunostained for p53 and observed under a fluorescence microscope. Methanol treated 
cells were used as negative control. Figure 3.15 show that p53 is spread out all over the 
cytoplasmic region in case of control cells unlike Dsz A1 treated cells where p53 is 
specifically localised in the nuclear region. 
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Figure 3.15: Nuclear localisation of p53 
Immunofluroscent staining of A-549 cells treated with methanol (control, A) and Dsz A1 (17.1 pM, B) 
for overnight shows that p53 (green) is confined to the cytoplasmic region in case of methanol 
whereas it is localised in the nucleus upon treatment of the cells with Dsz A1. 
 
3.6.2 Shuttling of Mdm2 
A feedback loop runs between p53 and Mdm2 wherein Mdm2, an oncoprotein (Mayo and 
Donner, 2001) is phosphorylated by Akt and moves into the nucleus, where it interacts with 
p53 inhibiting its transcriptional activity and targets it for proteasomal degradation. To see 
the effect of Dsz A1 on shuttling of phospho-Mdm2 within a cell, A-549 cells were incubated 
with Dsz A1 at 17.1 pM for overnight. Methanol treated cells were taken as negative control. 
Cells were stained with a phospho-Mdm2 antibody from mouse and were made visible by 
using a secondary antibody anti-mouse Alexa® Fluor 488. Methanol treated cells showed 
phospho-Mdm2 localized in the nucleus compared to cytoplasmic location on treatment with 
Dsz A1 (Figure 3.16). 
 
Figure 3.16: Shuttling of Mdm2 
Immunofluroscent staining of A-549 cells with methanol (control, A) and Dsz A1 (17.1 pM, B) for 
overnight shows that p-Mdm2 (green) is confined to nuclear region in case of methanol whereas 
phosphorylated mdm2 moves out of the nucleus upon treatment with Dsz A1. 
 
(A)
AA)
A) 
(B) 
(A) (B) 
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3.6.3 Effect of Dsz A1 on phosphorylation state of p53 
Earlier results showed the effect of Dsz A1 on p53 localization. So to identify any changes on 
the phosphorylation state of p53, KB-3-1 cells were treated with various concentration of Dsz 
A1 and methanol as negative control for overnight. The lysate was subjected to Western blot 
and probed for phosphorylated p53 and GAPDH. GAPDH served as loading control. As can 
be seen from Figure 3.17, cells treated with Dsz A1 at pico molar range showed an 
increased level of phosphorylation in a concentration dependent manner when compared to 
the control. 
 
Figure 3.17: Dsz A1 induces phosphorylation of p53 
KB-3-1 cells treated with Dsz A1 at various concentration for overnight showed an increase in 
phosphorylation of p53 compared to methanol (C) treated cells. GAPDH is taken as the loading 
control. 
The change in the phosphorylation state of p53 based on Western blot is also depicted 
graphically in terms of their intensities in Figure 3.18.  
        
Figure 3.18: Induction of phosphorylation of p53 by Dsz A1 
Dsz A1 induces a concentration dependent increase in the phosphorylation state of p53 in KB-3-1 cell 
lysate treated at various concentrations for overnight and later probed for phospho-p53 through 
Western blot. 
 
Dsz A1 0.01 pM 0.13 pM 1.3 pM C 
p-p53 (53 kDa) 
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3.6.4 Effect of Dsz A1 on PI3K/Akt pathway 
Based on the influence of Dsz A1 on p53 and role of p53 in PI3 kinase pathway as described 
earlier, it was suspected that Dsz A1 might have a target in this pathway which is often 
dysregulated in cancer cells. To investigate this hypothesis, a lysate was prepared from KB-
3-1 cells treated with Dsz A1 at various concentrations for overnight and probed for changes 
in various proteins involved in the pathway. In normal scenario a decrease in transcriptional 
activity of p53 causes decrease in stability of PTEN which thereby allows the PI3K/Akt 
pathway to carry on which involves an increase in phosphorylation of PDK1 and Akt, hence 
aiding in cell growth and proliferation. On the other hand cells treated with Dsz A1 showed an 
increase in the phosphorylation state of p53 which might allow an increased stability of 
PTEN protein (Figure 3.19). 
 
Figure 3.19: Dsz A1 might induce PTEN stability 
Lysate prepared from KB-3-1 cells treated with Dsz A1 at various concentration showed slight 
increase in PTEN protein compared to methanol (C) treated cell lysate. 
If PTEN attains stability, it would cause an inhibition of the PI3K/Akt pathway by decreasing 
the phosphorylation of various downstream proteins. Therefore, lysates from KB-3-1 cells 
treated with various concentrations of Dsz A1 were subjected to Western blot and probed 
with an anti-phospho PDK1, anti-total PDK1, anti-phospho Akt and anti-total Akt. Figure 3.20 
shows that Dsz A1 inhibited the phosphorylation of both PDK1 and Akt i.e., Dsz A1 induces 
an inhibition of the PI3K/Akt pathway. 
 
Figure 3.20: Dsz A1 inhibits the PI3K/Akt pathway 
Lysates prepared from KB-3-1 cells treated at various concentration of Dsz A1 showed a 
concentration dependent inhibition of the phosphorylation of PDK1 and Akt as compared to methanol 
(C) treated cells, i.e., the .PI3K/Akt pathway was inhibited. 
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3.6.5 Verifying the target of Dsz A1 with a DARTS approach 
It was hypothesised that Dsz A1 could be binding directly to PTEN, thus activating it and as a 
result antagonising the PI3K/Akt pathway. To investigate this point a drug affinity responsive 
target stability (DARTS) approach was used. This approach is based on the principle that a 
protein is less susceptible to protease digestion when bound to a ligand than when it is free 
due to stabilization of protein’s folded state (Lomenick et al., 2009). Lysate from KB-3-1 cells 
were incubated with Dsz A1 at various concentrations i.e., 66 nM, 6 nM, 0.6 nM and 0.06 nM 
for two hours on ice. This was followed by Pronase® digestion for 30 min at 37°C. Methanol 
was taken as the negative control. A cell lysate treated with Dsz A1 but not digested with 
Pronase® was taken as the positive control. Pronase® digestion was stopped by heating with 
SDS loading dye for 12 min at 96°C. The samples were separated by SDS-PAGE. A 
concentration dependent protection of a protein band around 50 kDa was noticed. PTEN 
protein has a molecular mass of 54 kDa. So this experiment was followed with Western blot 
wherein the protein bands after transferring it from the gel onto a nitrocellulose membrane 
were probed using an anti-PTEN antibody. The blot was later re-probed for GAPDH using an 
anti-GAPDH antibody which served as a loading control for the protein. As can be seen from 
Figure 3.21, the Dsz A1 treated lysates showed a concentration dependent protection for 
PTEN. 
       
Figure 3.21: DARTS approach with Dsz A1 
Lysate prepared from KB-3-1 cells was incubated with Dsz A1 at varying concentrations and later 
subjected to Pronase
®
 digestion. A methanol treated lysate (-) which was also digested served as 
negative control whereas a Dsz A1 treated but not digested lysate was taken as the positive control. 
Dsz A1 showed a concentration dependent protection. GAPDH was used as loading control. 
 
3.6.6 PTEN knockdown studies 
To further verify that PTEN is the target for Dsz A1 and it plays a role in the Akt pathway 
inhibition, PTEN in KB-3-1 cells was knocked down. The KB-3-1 cells were first transfected 
with siRNA PTEN for 48 h to knockdown PTEN. Negative control siRNA was used which is 
designed to have no known target in the cells. The transfected cells were later incubated 
with Dsz A1 for overnight. Lysate from the knockdown cells were subjected to Western blot 
to check for the knocking down efficiency which is shown in Figure 3.22. Panel A shows the 
Western blot analysis with siRNA PTEN and negative control using scrambled siRNA. 
PTEN (54 kDa) 
 
GAPDH 
Dsz A1 66 nM 6.6 nM 0.6 nM 0.06 nM - 66 nM 
Pronase® + + + + + - 
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GAPDH was used as a loading control Graphical representation of knockdown efficiency of 
siRNA PTEN is shown in panel B. 
 
Figure 3.22: siRNA PTEN knockdown study for PTEN 
Knockdown efficiency in KB-3-1 cell lysate is shown in panel A with Western blot probing using an 
anti-PTEN antibody. Scrambled siRNA is taken as the negative control which does not affect any 
known target in the cell. GAPDH was the loading control. A graphical representation of the respective 
protein band intensities are shown in panel B, where means and standard deviations from two 
experiments are given. 
The lysate of knockdown cells treated with Dsz A1 was used to check the effect on the 
phosphorylation state of Akt. The lysate was prepared after treating transfected KB-3-1 cells 
with 1.3 pM Dsz A1, subjected to Western blot and probed with an anti-phospho-Akt. As 
shown in Figure 3.23A, there is a clear reduction in the phosphorylation state of Akt in the 
normal KB-3-1 cell lysate as compared to the knock down cell lysate which does not have 
PTEN anymore for it to decrease the phosphorylation of Akt. This proves that Dsz A1 needs 
the presence of PTEN in cells for inhibiting cell growth and proliferation through inhibition of 
PI3K/Akt pathway. Figure 3.23B shows a graphical representation of the mean blot intensity 
with their standard deviation obtained from duplicate experiments. 
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Figure 3.23: Effect of Dsz A1 in PTEN knockdown KB-3-1 cells 
Lysates were prepared after treating the knockdown cells with Dsz A1 (1.3 pM) and probed for 
phospho-Akt by Western blotting. Panel A shows a clear reduction in the phosphorylation state of Akt 
in case of a normal cell lysate as compared to a non-reduced phosphorylation in a Dsz A1 treated 
knockdown cell lysate (C). GAPDH was taken as the loading control for both normal and knockdown 
lysates. Panel B and D shows a graphical representation of the mean intensities with their respective 
standard deviation. 
3.6.7 Influence of PTEN on apoptosis 
Normal and knockdown cell lysates were used to check for the involvement of PTEN in 
apoptosis. The level of apoptosis was determined on the basis of mono- and 
oligonucleosomes in cell lysates produced in case of induced cell death. As can be seen 
from Figure 3.24 the level of apoptosis is greatly reduced in lysate prepared from PTEN 
knockdown cells as compared to the normal cells, both treated with Dsz A1 at 1.3 pM. 
Control 1.3 pM 
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p-Akt 
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Figure 3.24: Level of apoptosis in normal and knockdown KB-3-1 cells treated with Dsz A1 
Normal cells and those that were knocked down with siRNA PTEN were treated with Dsz A1 (1.3 pM). 
The level of apoptosis was determined by measuring induced mono and oligo-nucleosomes in the 
cells. There is drastic reduction of apoptosis in lysate from knockdown cells compared to the normal 
one despite their Dsz A1 treatment. 
 
3.6.8 Prediction of the binding domain of Dsz A1 in PTEN 
As all experiments pointed to PTEN being a direct target of Dsz A1, docking studies with the 
known protein structure of PTEN were carried out to predict the binding domain of Dsz A1 
using the software Autodock (version 4). The crystal structure of PTEN was obtained from 
Protein Data Bank (accession number 1D5R (Lee et al., 1999)). It consists of a 179-residue 
N-terminal domain (phosphatase domain) and a 166-residue C-terminal domain. The 
signature motif HCXXGXXR is present as also in the active sites of protein tyrosine 
phosphatases (PTPs) and dual specificity protein phosphatases (DSPs). The structure of 
Dsz A1 used for this study is shown in Figure 3.25. 
RESULTS 
 
69 
 
 
Figure 3.25: Structure of Dsz A1 used for docking study 
From docking studies, PTEN was found to bind primarily at thr319 and two arg172, 173 with the 
epoxide ring of Dsz A1 (Figure 3.26B). The binding energy of this interaction was found to be 
-10MeV. Interactions between whole PTEN protein and Dsz A1 can be seen in Figure 3.26A. 
 
Figure 3.26: Docking site for Dsz A1 on PTEN protein 
Crystal structure of PTEN protein was obtained from Protein Data Bank (Id: 1D5R) and was docked 
with Dsz A1 using Autodock (v4). Panel A showing the whole protein docking with Dsz A1. Panel B 
shows the major interaction of the epoxide ring of Dsz A1 with amino acids, threonine and two 
arginines at 319, 172 & 173 positions, respectively. 
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3.7 Identification of the mode of action of disorazol Z 
As mentioned earlier in sections 3.5.1.2 and 3.5.2.1, Dsz Z seems to affect not only the 
microtubular structures of incubated cells but could also somehow affect kinase signalling 
pathway. Since belonging to the same chemical class, we wanted to investigate if the target 
or the pathway which Dsz A1 affects would be similar for Dsz Z too First the effect of Dsz Z 
on cellular microtubules was investigated. 
3.7.1 Influence of Dsz Z on tubulin structure 
Based on the results of impedance measurements, Dsz Z clustered with microtubule 
affecting compounds. So to check this affect, PtK2 cells were cultured on sterile coverslips 
overnight and treated with Dsz Z at a concentration of 9.4 nM. Cells treated with methanol 
were taken as negative control. The cells were fixed and immunostained with an anti-α-
tubulin antibody. As can be seen from Figure 3.27, Dsz Z induced multinucleated cells 
showing microtubular bundling. 
 
Figure 3.27: Dsz Z induces changes in microtubular structure 
PtK2 cells were treated with Dsz Z (9.4 nM) (panel B) and methanol (panel A) for overnight. Cells 
were stained for α-tubulin (green) and nuclei (blue). Cells treated with Dsz Z showed microtubular 
bundling and multinucleated cells unlike methanol treated ones which have one nucleus each and 
normal microtubular network. 
3.7.2 Effect of Dsz Z on p53 localization 
To check the effect of Dsz Z on the localization of p53, A-549 cells were incubated with Dsz 
Z (67 pM) for overnight at 37°C and immunostained with an anti-p53 antibody. Methanol 
treated cells were taken as negative control. As can be seen from Figure 3.28 p53 is 
localised in the nucleus upon treatment with Dsz Z as compared to the cytoplasmic location 
of p53 in methanol treated cells. The effect closely resembles that of Dsz A1.  
(A) (B) 
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Figure 3.28: Effect of Dsz Z on p53 localization 
A-549 cells were treated with Dsz Z at a concentration of 67 pM (panel B) and methanol (panel A) for 
overnight, fixed and stained with an anti-p53 antibody (green). Dsz Z treated cells show nuclear 
localization of p53 compared to cytoplasmic location in methanol treated cells. 
3.7.3 Elucidating the target of Dsz Z with a DARTS approach 
A DARTS approach was carried out with cell lysates prepared from KB-3-1 cells that have 
been treated at various concentrations of Dsz Z. A cell lysate treated with methanol was 
taken as negative control whereas a lysate treated with Dsz Z but not digested with 
Pronase® was considered positive control. Figure 3.29 depicts a Coomassie Blue staining 
after SDS-PAGE separation. It shows a protein band having molecular weight above 75 kDa 
that seemed to be protected in a concentration dependent manner.  
(A) (B) 
(B) 
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Figure 3.29: DARTS approach with Dsz Z 
Cell lysate prepared from KB-3-1 cells were incubated with Dsz Z at various concentrations and 
subjected to a DARTS approach using Pronase
®
 as the proteolytic enzyme. After SDS-PAGE the gel 
was stained with Coomassie Brilliant Blue. Methanol treated lysate (C) was the negative control and 
Dsz Z treated but not digested was taken as positive control. Dsz Z protected a protein band running 
above the 75 kDa mark. 
Following the indication that Dsz A1 is affecting the PI3K/Akt pathway, we tried to probe for 
the p85 regulatory unit of PI3 kinase as a potential target of Dsz Z. Hence the experiment 
was repeated with the same set of controls using an anti p85 antibody. This blot was re-
probed for GAPDH which served as loading control. As can be seen from Figure 3.30, Dsz Z 
treated samples shows a concentration dependent protection for p85. 
 
Figure 3.30: DARTS with Dsz Z followed by Western blot for p85 
KB-3-1 cell lysate treated with varying concentration of Dsz Z were proteolytically digested with 
Pronase
®
 and loaded onto SDS-PAGE. Methanol treated lysate (C) was taken as negative control and 
Dsz Z treated non-digested one was the positive control. The lysate was subjected to Western blotting 
and probed with an anti-p85 antibody. Dsz Z shows a concentration dependent protection for the 
regulatory subunit of PI3 kinase, p85. GAPDH was used as loading control. 
p85 (85 kDa) 
GAPDH 
Dsz Z(µM) 134 13.4 1.34 0.13 C 134 
Pronase® + + + + + - 
 
>75 kDa 
Dsz Z (µM) 134 13.4 1.34 C 134 
Pronase® + + + + - 
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3.7.4 Effect of Dsz Z on PI3 Kinase pathway 
The DARTS result showed that the p85, regulatory subunit of PI3 kinase is being bound by 
Dsz Z. To verify if and how Dsz Z affects the phosphorylation state of p85, KB-3-1 cells were 
treated for overnight with Dsz Z at varying concentrations and subjected to Western blot 
analysis with an anti-phospho-p85 antibody. As can be seen from Figure 3.31, there is 
concentration dependent decrease in the phosphorylation state of p85. Methanol treated 
cells were taken as the negative control. 
 
Figure 3.31: Effect of Dsz Z on phosphorylation state of p85 
KB-3-1 cells were treated with Dsz Z at varying concentration for overnight before preparing the 
lysates. These were loaded onto SDS-PAGE and probed for p-p85 state using an anti-p-p85 antibody. 
A methanol treated lysate (C) was taken as negative control. GAPDH was taken as the loading 
control. 
Like Dsz A1 which affects the protein kinase B or Akt phosphorylation, Dsz Z was also tested 
for the same effects but the results were negative. Dsz Z does not affect Akt but another 
downstream protein of the PI3 kinase pathway called SGK1 which is structurally quite similar 
to Akt and also supports cell growth and proliferation upon phosphorylation by the PI3 kinase 
pathway. As can be seen from Figure 3.32, there is concentration dependent decrease in the 
phosphorylation state of proteins involved in PI3 Kinase/SGK pathway. In normal scenario 
when p85 regulatory subunit of PI3 kinase is phosphorylated, its inhibitory effect on the 
catalytic subunit p110 is released for p110 to carry out the downstream effect of 
phosphorylating PDK1 which in turn phosphorylates SGK1, thereby helping in cell growth. 
But when the cells are treated with Dsz Z, it inhibits the phosphorylation of p85, thereby 
stalling PI3K/SGK pathway. 
 
Figure 3.32: Effect of Dsz Z on PI3K/SGK pathway 
KB-3-1 cells were treated with Dsz Z at various concentrations for overnight and lysates prepared 
from them were loaded onto SDS-PAGE. The blot was probed for p-PDK1 and p-SGK1 using an anti-
p-PDK1 and anti-p-SGK1 antibodies respectively. Methanol treated lysate (C) and GAPDH were 
taken as negative and loading control respectively. There is gradual decrease in the phosphorylation 
state of both phospho proteins upon Dsz Z treatment. 
p-PDK1 
p-SGK1 
GAPDH 
Dsz Z 0.13 
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3.7.5 p85 Knockdown studies 
To further verify the target of Dsz Z, knockdown studies were carried out. Based on the 
DARTS results, p85 was chosen for knockdown. L-929 cells were transfected with siRNA 
p85α for 48 h for efficient knockdown. Scrambled siRNA was chosen as the negative control 
as it does not affect any known target in the cell. To check for the efficiency of p85α 
knockdown, a lysate was prepared from transfected L-929 cells and subjected to Western 
blotting. The level of p85α was probed using an anti-phospho p85α antibody as can be seen 
from Figure 3.33A. Panel B shows a graphical representation of the knockdown efficiency. 
 
Figure 3.33: p85α knockdown efficiency 
L-929 cells were transfected with p85α siRNA for 48 h before preparing the lysate for Western blot 
analysis. The blot was probed using an anti-phospho p85α antibody to check for the knockdown 
efficiency (panel A). Scrambled siRNA was used as negative control. Panel B shows the quantitative 
measurement based on the band intensity. Means and standard deviation from two experiments are 
given. 
The same transfected L-929 cells were treated with 134 nM of Dsz Z for overnight before 
preparing the lysate. To verify the role played by p85α in the downstream process of SGK1 
phosphorylation and thereby helping the cells to grow and proliferate, Dsz Z treated 
knockdown lysate was subjected to Western blotting and probed for any change in the 
phosphorylation of SGK1 using an anti-phospho SGK1. To compare the change, a lysate 
from normal cells was also used after treating the cells overnight with same concentration of 
Dsz Z. As shown in Figure 3.34, there is reduction in the inhibiting effect of Dsz Z on the 
phosphorylation state of SGK1 in the knockdown cells compared to normal cells. Graphical 
representation of the same is shown in Figure 3.34 B&D. 
(A) 
Scrambled 
siRNA 
siRNA 
p85α 
p85α 
wt 
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Figure 3.34: Effect of p85α knockdown on phosphorylation of SGK1 
L-929 cells were transfected with p85α siRNA for 48 h and treated with Dsz Z (134 nM) for overnight. 
Both treated normal and knockdown cell lysates were subjected to Western blotting and probed using 
an anti-phospho-SGK1 and an anti GAPDH antibody. Panel A shows that the level of SGK1 
phosphorylation is reduced on treatment with Dsz Z in normal lysate unlike in panel C the knockdown 
cells are no longer competent for the Dsz Z action. GAPDH is taken as loading control. Panel B and D 
shows the graphical representation of p-SGK1 with their means and standard deviation from two 
experiments. 
3.7.6 Role of p85 in caspase 3/7 activity involved in apoptosis 
To check for the role played by p85 in apoptosis, caspase 3/7 activity was measured for both 
normal and knockdown cell lysate treated with Dsz Z. Caspases are members of cysteine-
aspartic acid specific proteases which play an effector role in apoptosis. Caspase 3/7 activity 
was measured using a Caspase 3/7 Glo® kit provided by Promega®. The luminescence 
signal provided is directly proportional to the level of caspase activity which in turn indicates 
(C) 
Knockdown cells 
Control 134nM 
 
p-SGK1 
 
GAPDH 
(D) 
(A) 
Normal cells 
Control 134nM 
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the level of apoptosis. As can be seen from Figure 3.35, the level of caspase activity in Dsz 
Z treated knockdown cells is reduced when compared to normal cells. This indicates that 
p85 is required for apoptosis to be carried out by Dsz Z. 
 
Figure 3.35: Role of p85 in apoptosis induced by Dsz Z 
L-929 cells were transfected with p85α siRNA for 48 h and treated with 134 nM of Dsz Z for overnight 
before preparing the lysate. Dsz Z treated normal L-929 lysate and p85α knockdown lysate were 
measured for Caspase 3/7 activity. Caspase activity induced in knockdown cells is reduced when 
compared to normal cells. 
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4 Discussion  
Natural products continue to provide a variety of “lead” structures which are used as 
templates for the development of new drugs. The majority of these leads are secondary 
metabolites from microbial system (Li and Vederas, 2009). Advances in various bioassays 
and in synthetic chemistry have combined to make natural products a cost effective source 
of leads (Borris, 1996). Many times nature not only provides us with bioactive compounds 
but those compounds also allow us to dwell on concept of evolutionary processes and their 
optimisation. One may think that isn’t it enough knowing that a compound is biologically 
active. Yes, but the need to know how these small molecules act within a cell (MoA) 
becomes important from past experiences of high attrition rate (Swinney and Anthony, 2011) 
observed for lead structures among pharmaceutical industries and it also helps to completely 
utilize its full potential by population-specific targeting. 
The objective of this study was to make use of in-house established high content analysis 
approaches, viz., image analysis and impedance profiling to obtain hints of the MoA of small 
molecules of interest. An alkaloid jerantinine E and four polyketides namely paleo-soraphen 
A & B, disorazol A1 and Z. were the compound of interest which were shown to have 
different mechanism of action and targets. High content analysis was used not only for 
identifying the MoA but was also compared to see if and how the indications provided by two 
approaches are different.  
4.1 High content analysis (HCA) 
High content analysis is a platform designed to define spatial and temporal activities of 
genes, proteins, and other cellular constituents in a living cells (Giuliano et al., 2003). 
Identification of small molecule modulators of protein function, and the process of 
transforming them into a “lead” are key activities in drug discovery (Bleicher et al., 2003). 
The study presented made use of HCA in two different cell-based assays, one being a cell 
invasive, labelling technique and the other being a label-free approach. 
HCA by automated microscopy is a labelling technique wherein the cells are incubated with 
the compound of interest and later fluorescently tagged with a range of antibodies 
representing cellular proteins. Impedance monitoring is a label-free technique depending 
greatly on changing cell morphology. 
4.1.1 Image analysis 
Automated microscopy provides with a powerful tool for analysing the physiological state of 
the cell with high throughput and high information content when incubated with the 
compound of interest (Mitchison, 2005). It allows rapid visualization of a large group of cells 
and phenotypic analysis in a quantitative manner (Starkuviene and Pepperkok, 2007). In this 
study HCIA was first carried out for the reference compound who’s MoA are well-
established. Cells when treated with these compounds in optimum concentration caused 
morphological and physiological changes. These changes were observed by fluorescently 
tagging the cells with appropriate antibodies and nuclear marker. Images were acquired 
using an automated microscope with some pre-defined application modules. Acquired 
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images were analysed and statistical analysis was carried out. Hierarchical clustering 
provided us with clusters of compounds having similar MoA, though all reference 
compounds did cluster with one another at various Euclidean distances forming a complete 
family of clusters. The reference library included 63 commercially available compounds 
(Table 2.3). Figure 3.1 shows profiles of all the reference compounds within their clusters. 
Many clusters showed compounds with the same MoA but on few occasions, compounds 
with dissimilar MoA clustered together. This could be due to some off-targets effects. For 
example, argyrin A clustered with microtubule affecting compounds, though it is known to be 
a proteasome inhibitor. p53 localizes to microtubules and in response to DNA damage, it is 
transported to the nucleus (Giannakakou et al., 2002) and hence being activated whereas 
for p53 to be degraded it requires proteasomes. So probably argyrin A stops proteasomal 
degradation of p53 and that made it to cluster with MT affecting compounds. Another cluster 
grouped MG132, a proteasome inhibitor, with kinase pathway affecting compounds. It has 
been shown that inhibition of cyclin-dependent kinase is regulated by proteasome (Pagano 
et al., 1995). Also it is not necessary that compounds in the same cluster are related to one 
another depending on their MoA but they could cluster together due to various reasons. If 
the test compound has a novel MoA that is not represented by the reference compounds, it 
is not possible to find a matching profile. Hence it clusters with the closest matching profile. 
With respect to the concentration used, sometimes compound always cluster in a one 
particular group irrespective of concentration but sometimes at lower concentrations 
compounds might interfere with p53 protein and at higher concentration the MT network is 
affected (Giannakakou et al., 2002). So clustering changes from a p53 affecting compound 
to MT effectors.  
Transformed data can be analysed not only by using hierarchical cluster analysis providing 
us with heat maps as mentioned above but with the help of non-hierarchical cluster analysis 
compounds could be grouped. Self-organizing maps (SOMs) is a simple representation of 
similarity between the clusters. It does not necessarily provide us with hints about the 
compound’s mechanism. All compounds are separated in a pre-determined number of 
clusters. 13 descriptors were taken into consideration and their average profiles are shown 
with the help of a graph line within each cluster of SOM. (Figure 3.2) Another method within 
non-hierarchical cluster analysis is principal component analysis (PCA) which places all the 
compounds within a 3D biological space. (Figure 3.3) This helps to identify outliers which 
could indicate a totally novel MoA.  
Out of all the methods used in this study, heat maps generated by using hierarchical cluster 
analysis provided sound information about the MoA of the reference compounds. 
4.1.2 Impedance profiling 
The xCELLigence system is based on impedance measurement of the cells seeded on gold 
electrodes integrated in the well bottom of an E-plate. Incubation of cells with compounds 
causes morphological and physiological changes in the cell status which is reflected in 
change of impedance. These changes were measured over a period of few days. Acquired 
data were transformed to provide Z-scores which were later used in statistical analysis to 
generate a heat map. Euclidean distances were used to form a similarity matrix which 
grouped all the 63 reference compounds in different clusters based on different MoA. Figure 
3.4 shows different clusters with few compounds highlighted. Most of the compounds 
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clustered in correct groups like box 3, 4, 5 and 6 but box 1 shows clustering of compounds 
inhibiting transcription via different ways along with cytochalasin D which is an actin 
inhibiting compound. A closer look to the dendrogram shows that though cytochalasin D is in 
the same cluster it has a big distance to other members. According to the dendrogram 
cytochalasin D seems to be closer to the compounds in box 2 containing latrunculin B and 
rhizopodin A which affects actin. 
Thus, it becomes clear that as much as it is important for one to see the clusters at the right 
hand side of the heat map, it is also necessary to complement it with the Euclidean distance 
provided in the dendrogram to ensure the certainty of the hint. 
Several strengths and weaknesses were observed for both the methods utilized in this study, 
viz., automated microscopy and xCELLigence. Automated microscopy as mentioned earlier 
is a cell invasive labelling method which forces one to obtain only an end-point result of the 
assay whereas xCELLigence on the other hand is a kinetic assay as it measures the change 
in impedance over a period of time in the presence of the compound. It could provide us with 
information about short as well as long-term effect response of the drug on cells. Despite of 
giving only end-point results, image profiling could be of advantage when analysis of 
phosphorylated proteins is decisive. It is not investigated as to how change in the 
phosphorylation state of the proteins affects the impedance reading but certainly this change 
will be detected by analysing their images which makes it one of the strength of automated 
microscopy. However, both approaches should be able to provide us with hints towards the 
MoA for test compound when included along with well-established reference compounds by 
comparing the test profile with that of the known MoA profiles. 
Having said that, the presented study also pointed out that both the methods can only be 
used as a tool to get hints towards the MoA of a compound. One needs to remember that 
the clusterings are just indicators of possible targets and not sure shot protein/pathway 
target identifiers. They could also be indicating some secondary targets. 
4.2 Mechanism of selected bioactive compounds 
In terms of cytotoxicity, jerantinine E showed its activity in lower micromolar range (IC50 = 1.9 
µM) whereas paleo-soraphen A & B, genetically inspired derivatives of soraphen A were 
found to be much less active in cancer lines On the other hand the two members of the 
disorazol family, disorazol A1 and Z showed subnanomolar activity in a variety of cancer cell 
lines (IC50 = 0.0016 nM and 0.24 nM, respectively in KB-3-1 cells). Based on the results of 
high content analysis, the mechanisms of these compounds were elucidated. 
4.2.1 Jerantinine E 
Jerantinine E, one of the seven Aspidosperma indole alkaloids isolated from leaf extracts of 
the Malayan plant Tabernaemontana corymbosa showed a cytotoxicity against KB-3-1 cells 
which is rare among Aspidosperma alkaloids. The mechanism for this bioactivity was not 
known (Frei et al., 2013). Impedance profiling of jerantinine E (Jer E) with L-929 cells 
showed a profile (Figure 3.5) similar to those of microtubule affecting compounds like 
colchicine which directed our investigation towards tubulin based assays. 
Immunofluorescence staining of PtK2 cells treated overnight with Jer E showed (Figure 3.6) 
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multinucleated cells to nearly complete disruption of microtubules at 10 µg/mL as seen in 
case of cells treated with colchicine, an active alkaloid of Colchicum (Molad, 2002). These 
results made it very likely that Jer E is inhibiting tubulin polymerisation. 
This assumption was assessed by (Frei et al., 2013). Jerantinine E inhibited tubulin 
polymerisation with an IC50 of 0.45 µM (Frei et al., 2013). In terms of % tubulin 
polymerisation inhibition Jer E showed 79 % compared to colchicine at 75 % (statistically 
significance with p< 0.05 [Student t test]). 
The ability of tumour cells to infiltrate and disseminate widely is what makes them malignant 
(Nabeshima et al., 2002). Therefore, inhibition of cell migration by Jer E was also observed 
by (Frei et al., 2013) for four cancer cell lines (MCF-7, MDA-MB-231, A-549 and HT-178). 
These cell lines were exposed for 15 h at 2.5 µM and 15.6 µM. Migration inhibition was most 
pronounced for the breast cancer cell line, MCF-7 and MDA-MB-231 (Frei et al., 2013). 
4.2.2 Paleo-soraphen A & B 
For a large variety of polyketides at least one of the enzymatic steps seen within the PKS is 
non-functional. Paleo-soraphen A & B were synthesised chemically by following the 
structures predicted by an intact polyketide synthases modular assembly of soraphen A. 
Such genetic derivatives can help us to understand if and how the biological behaviour 
changes and give insights into the evolution of compounds. 
Soraphen A, a potential antifungal and antitumor compound, inhibits the eukaryotic acetyl-
coenzyme A carboxylase (ACC). Genetic analysis of the appropriate PKS identified two 
positions in the soraphen structure which differed from the genetically expected outcome 
(Schupp et al., 1995; Wenzel et al., 2006). The presence of double bond (Figure 1.14) 
between C9-C10 is proposed to be a consequence of postketide transformation whereas the 
absence of a double bond between C2-C3 in soraphen A is due to the inactivity of the 
dehydratase module in the domain (Schupp et al., 1995). Such structural variation may 
change its bioactivity. Impedance profiling showed that paleo-soraphen A has a similar 
profile to that of its parent compound, soraphen A, whereas paleo-soraphen B clustered with 
the topoisomerase I inhibitor, camptothecin (Figure 3.7). 
Based on above results and previously known activity of soraphen A as antifungal, genetic 
derivatives were tested against fungi. Only paleo-soraphen A showed some activity against 
Pythium debaryanum (Lu et al., 2013). 
With respect to paleo-soraphen B, its effect was compared to that of camptothecin by 
immunofluorescence staining of PtK2 cells. Topoisomerase I is shown to have a protein 
kinase activity that phosphorylates the splicing factor SC-35. These are found in speckles 
which occupy nuclear space. mRNA transcription and processing takes place in these 
speckles. Inhibition of mRNA transport from nucleus to cytoplasm causes rounding, 
enlargement of speckles and the accumulation of splicing factors within them. The activity of 
SC-35 is regulated by a phosphorylation-dephosphorylation system. Like camptothecin, 
paleo-soraphen B causes a rounding of speckles and equal distribution within the nucleus 
(Figure 3.8) unlike soraphen A and paleo-soraphen A. These speckles were quantified in 
terms of their average size. It was shown that both camptothecin and paleo-soraphen B 
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caused the average size of the speckles to be much smaller compared to controls (Figure 
3.9). 
The effect of paleo-soraphen A on eukaryotic ACC was found to be mild. It requires further 
investigation. But it supports the concept of evolutionary optimization (Lu et al., 2013). 
Genetic derivatives do require further investigations with respect to their mechanisms. 
4.2.3 Disorazol A1 
Disorazol A1 (Dsz A1) was isolated from the culture broth of the myxobacterium Sorangium 
cellulosum So ce12. It is active against many filamentous fungi (MIC = 0.1 to 1 µg/mL) but 
not yeasts and bacteria. Dsz A1 shows cytotoxicity in a subnanomolar range in mammalian 
cells (Table 3.1). 
Earlier results with Dsz A1 showed that it inhibits tubulin polymerisation in a concentration 
dependent manner but independent of microtubule-associated proteins (MAPs). At lower 
concentrations immunofluorescence staining also showed a nuclear accumulation of tumour 
suppressor protein p53 (Elnakady et al., 2004). To investigate this point and its role in 
increased cytotoxicity, a detailed study of mode of action was carried out. 
When Dsz A1 was applied to cells for their impedance profiling it clustered with compounds 
effecting microtubule (Figure 3.10). On the other hand in image profiling, it clustered with a 
totally different group of compounds i.e., kinase pathway effectors. These interesting findings 
could reflect the results obtained by the p53 investigations. As described earlier HCA 
methods can point towards different targets and in this case the image profiling seemed to 
be more sensitive for phosphorylated targets than the impedance profiling. 
At picomolar levels of Dsz A1, the “zip-code” (O’Brate and Giannakakou, 2003) of p53 
protein changed from cytoplasm to nucleus (Figure 3.15) which could be explained by the 
observation that Dsz A1 inhibits phosphorylation of Akt. In a normal scenario, when Akt is 
phosphorylated it activates or inhibits various downstream proteins, one of them being 
Mdm2 (Figure 1.9) which is activated by phosphorylation. Mdm2 (Mouse double minute 2) 
belongs to the family of E3 ubiquitin ligases. It shuttles between the nucleus and the 
cytoplasm as it contains nuclear localization and nuclear export signals within its structure, 
(Liang and Clarke, 2001; Vargas and Ronai, 2002) and helps to downregulate p53 activity 
(Pei et al., 2012). Phosphorylation of Mdm2 obligates its translocation from cytoplasm to 
nucleus where it interacts with p53, inhibit its transcriptional activity and target it for 
proteasomal degradation. In our study we observed an increase in the phosphorylation state 
of p53 (Figure 3.17) and a cytoplasmic translocation of Mdm2 (Figure 3.16) upon Dsz A1 
treatment. 
Once p53 is being prevented from degradation, it induces an expression of a group of target 
genes which negatively regulate cell survival pathways like PI3K/Akt (Feng, 2010). These 
target genes involves the phosphatase enzyme PTEN which dephosphorylates PIP3 to PIP2 
(Figure 1.10). The presented investigation gave hints that the picomolar levels of Dsz A1 
might enhance the stability of PTEN. PTEN protein “tail” (residues 354-403) is necessary for 
stability of PTEN but also acts to inhibit its function by phosphorylating the tail (Vazquez et 
al., 2000). One would need to further investigate as to how Dsz A1 is stabilizing PTEN but at 
the same time being able to retain its activity. 
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Once PTEN stabilizes, it antagonizes the PI3K pathway. Once PIP3 is converted to PIP2, 
PH-domain containing proteins like PDK1 and Akt get de-recruited from the plasma 
membrane (Carracedo and Pandolfi, 2008) and there is reduced phosphorylation of PDK1 
and Akt. (Figure 3.20) Activated Akt is a well-established survival factor (Di Cristofano and 
Pandolfi, 2000). 
To confirm that Dsz A1 shows the above described effects by binding directly to PTEN, a 
DARTS approach was carried out which clearly showed a concentration dependent 
protection of PTEN from proteolysis. (Figure 3.21) PTEN is a well-established tumour 
suppressor gene that induces apoptosis and controls cell growth by inhibiting the PI3K/Akt 
pathway (Ming and He, 2012). 
Further confirming the role of PTEN, knockdown studies were done wherein PTEN was 
knockdown using siRNA PTEN in KB-3-1 cells. (Figure 3.22) Lysates prepared from these 
knockdown cells were probed for the level of phosphorylated Akt and compared with that of 
normal cells (Figure 3.23). These investigations confirmed that PTEN is the target protein of 
Dsz A1. It’s binding leads to a reduced phosphorylation of Akt and thereby inhibiting cell 
proliferation. 
PTEN plays a critical role in DNA damage repair and DNA damage response thereby acting 
as guardian of genome integrity. (Ming and He, 2012; Shen et al., 2007). One of the DNA 
damage responses is apoptosis. The level of apoptosis was measured photometrically for 
lysates prepared from PTEN knockdown cells that were incubated with Dsz A1. Comparison 
with normal lysates (Figure 3.24) showed that PTEN is required for Dsz A1 induced 
apoptosis. PTEN might exert its tumour-suppressive effect through inhibition of cell-cycle 
progression or the induction of apoptosis as a consequence of blocking signalling pathways 
(Weng et al., 2001). Studies showed that Dsz A1 blocks the PI3K\Akt pathway which could 
explain the event of apoptosis. But inhibition of cell cycle progression (G2\M blockage) 
(Elnakady et al., 2004) might not be contributed by PTEN as PTEN-mediated cell-cycle 
arrest takes place at G1 (Eng, 2003) at least for MCF-7 cells. Therefore, probably cell cycle 
arrest and apoptosis are differentially regulated (Weng et al., 2001) in our case. 
Once we had the confirmation of the role of PTEN which was induced by Dsz A1, docking 
studies with PTEN protein (accession number: 1d5R) and Dsz A1 were carried out. (Figure 
3.26A) Major interactions were seen between Dsz A1 and PTEN protein at the amino acids, 
threonine319 and two arginine’s172, 173. (Figure 3.26B) Interactions with the arginine are in the 
phosphatase domain (residues 7-185) of the PTEN protein which is responsible of binding 
with the phosphoinositide substrates (Lee et al., 1999). One of the interactions of arginine is 
with the epoxide ring of Dsz A1 which is believed to contribute to an enhanced bioactivity. 
The interaction with thr319 belongs to the C2 domain (residues 186-351) of PTEN protein 
which binds to the phospholipid membrane.  
4.2.4 Disorazol Z 
Disorazol Z (Dsz Z) was produced by fermentation of the myxobacterium Sorangium 
cellulosum So ce1875. It was found to be effective against a range of tumour cells in 
nanomolar concentrations. (Table 3.1) It is as active in primary (HUVECs) as in tumour cells 
(e.g., KB-3-1). Conjugation of Dsz Z with the LHRH agonist peptide has shown to increase 
its activity in tumour cells with available LHRH receptors in breast, prostate and ovarian 
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cancers (Guenther et al., 2013). It was observed in the presented study that like Dsz A1, Dsz 
Z also is cytostatic in nature and not cytotoxic as it did not reach the IC90 mark. 
Impedance profiling of Dsz Z when treated at nanomolar levels showed that it clustered with 
colchicine, a microtubular effector and jerantinine E which was also found to be affecting 
microtubules (Figure 3.11). 
Image profiling on the other hand showed a clustering with argyrin A, a proteasome inhibitor 
and a kinase inhibitor, indirubin monoxime (Figure 3.12). Dsz Z shows a similar profile to that 
of argyrin A probably due to the involvement of p53. Proteasome inhibitors stabilize and 
accumulate p53 which leads to apoptosis (Lopes et al., 1997). For p53 to be transcriptionally 
active, it needs to enter the nucleus. Cells when incubated with Dsz Z showed a 
translocation of p53 to the nucleus as seen in case of Dsz A1 too (Figure 3.28). 
Based on these results Dsz Z was also checked for its role in the PI3 kinase pathway. 
The DARTS approach showed a protection of a protein band running above the 75 kDa 
marker. (Figure 3.29) Western blot analysis helped us to identify the protein being protected. 
The results were positive when the membrane was probed with an anti-p85 antibody. This 
showed that Dsz Z binds directly to the regulatory unit of PI3 kinase, p85. 
Once the target was identified, their downstream proteins were analysed. As described 
earlier, p85 is involved in the regulation of the PI3K pathway by inhibiting the catalytic unit, 
p110 of the PI3 kinase. The site of p85 with which it binds and inhibits p110 thereby stalling 
PI3 kinase is also the site where p85 is phosphorylated. If this phosphorylation takes place, 
p110 is free and activated (Cuevas et al., 2001) but if p85 is prevented from being 
phosphorylated as is done by Dsz Z, p85 is free to go and bind with p110 and thus 
inactivating PI3K pathway. Dsz Z showed a concentration dependent decrease in 
phosphorylation of p85 (Figure 3.31). 
Dsz Z was checked for its effect on the phosphorylation of Akt but results were negative, so 
the effect of Dsz Z was checked for other downstream proteins which might be involved in 
aiding cell growth. Literature talks about another cell survival signal involving a protein which 
is structurally similar to Akt (Brunet et al., 2001). This protein is independent of Akt but 
dependent on PI3 kinase for its activation and signalling. 
Dsz Z inhibits phosphorylation of a kinase PDK1 which is responsible for phosphorylation 
and activation of SGK1 dependent cell growth. (Figure 3.32) These results show that Dsz Z 
affects the PI3K pathway but its downstream effector is different.  
Knockdown studies of p85 showed that the presence of p85 (Figure 3.33) is required for 
further phosphorylation and activation of SGK1. As compared to the normal cells, 
knockdown cells were not able to prevent activation of SGK1. (Figure 3.34) Though the 
extent of phosphorylation of SGK1 in knockdown cells is higher than normal cells but there is 
no drastic reduction which can be explained by the fact that the regulatory unit isoform, p85α 
is encoded by PIK3R1 gene which also gives two shorter isoform, p55α and p50α through 
alternative-transcription sites and these individual isoforms show enhanced insulin sensitivity 
in absence of p85α and therefore activate PI3K signalling (Engelman et al., 2006; 
Okkenhaug and Vanhaesebroeck, 2001). A complete knockdown of the regulatory unit and 
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not just one isoforms could provide us with further details on the effect of Dsz Z on SGK1 
inhibition.  
Once the role of p85 was confirmed upon treatment with Dsz Z, its effect was assessed 
towards apoptosis. Caspase activity in lysates from knockdown cells incubated with Dsz Z 
was less compared to normal lysates indicating that p85 is required for a maximal induction 
of apoptosis by Dsz Z. p53 might also play a role in this effect as it stimulates the apoptotic 
pathway (Haupt et al., 2003). 
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5 Outlook 
High content analysis has helped us to narrow down the downstream approach in 
elucidating the mode of action of bioactive compounds, but these methods are far from being 
perfect. Further investigations could help to enhance the correct prediction rate of the mode 
of action of new compounds, e.g., by including more reference compounds and more 
descriptors, the latter being possible for image profiling. These will not only help to forgo the 
time spent on performing several experiments without knowing the possible target but most 
importantly reduce the attrition rate of drugs obtained from natural products. 
A new approach could be established wherein the descriptors of both image and impedance 
profiling are combined. This could provide with better indications than what is now being 
provided individually. Though first steps were made towards such an approach during this 
study but it does require more investigations before such a method will be available.  
All the selected bioactive compounds for this study showed different mechanisms of action. 
Jerantinine E was found to induce a depletion of microtubules in the cells and to inhibit 
tubulin polymerisation in vitro. Studies on the binding sites could give more insights in the 
mode of action. HCA of paleo-soraphen A & B was just a stepping stone for further studies 
as in this study it was only shown that paleo-soraphen A had a similar profile to that of 
soraphen A whereas paleo-soraphen B might affect topoisomerase I. Directly measuring the 
inhibition of ACC and topoisomerase activity could provide some more evidence to support 
the findings. Such genetic derivatives can also help us to understand the modular assembly 
of PKS or NRPS multi-enzyme system in more detail. Members of the disorazol family 
namely Dsz A1 and Z affected the same pathway (PI3K) but their downstream effector 
proteins and targets were different. Dsz A1 on one hand targets the phosphatase PTEN 
which antagonized the PI3K pathway which leads to down regulation of Akt protein whereas 
on the other hand Dsz Z targets p85, the regulatory unit of PI3 kinase which also down 
regulates the PI3K pathways but does not affect Akt. It affects another kinase, SGK1 which 
is also involved in regulation of cell growth. Surface plasma resonance (SPR) technique and 
co-crystallization study of the target with that of the small molecule could provide further 
insights in the binding of these small molecules to their respective targets. The disorazols 
are potential antitumor drugs. The most successful approach could be tumour targeting with 
synthetic derivatives that specifically deliver the compounds to the tumour cells. The 
disorazol moiety is then used as a warhead to kill the malignant cells.  
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